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 This dissertation is a compilation of three projects centered on enhancing 
the longevity of immune responses by tumor-reactive T cells. Chapter 3 of this 
dissertation examines the synergy of T cell functional enhancement via patient 
total body irradiation and the memory capacity of Tc17 cells. This work was 
published in the June 2015 edition of Clinical Cancer Research. Chapter 4 
investigates the durability of Th17 cells to preserve antitumor efficacy both during 
in vitro expansion and after infusion. This work was published in the March 2017 
edition of JCI Insight. Chapter 5 explores the potent enhancement of memory 
phenotype and antitumor efficacy of T cells following in vitro PI3K blockade using 
the small molecule inhibitor CAL-101. This work is in preparation for submission 
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JACOB STUART BOWERS. Generating Memory T cell Responses to Cancer:  
Three Approaches Towards a Cure. (Under the direction of CHRYSTAL PAULOS). 
Abstract 
The development of immunotherapies over the last three decades has 
dramatically improved treatment for late stage cancers. Among these therapies is 
adoptive T cell therapy (ACT), which enriches and expands autologous tumor-
reactive T cells for reinfusion to the patient. ACT has exploited the power of T cells 
to exert long-term immunity providing unprecedented responses, including 
complete remissions and cures. Three major benefits of ACT have emerged since 
the early trials: 1), ACT provides a window for preconditioning the patient. This 
allows transferred T cells to engraft in large numbers, become functionally 
enhanced, and be free of immunosuppressive pressure. 2), ACT allows for the 
selection of T cells with superior antitumor qualities for treatment. 3), The ex vivo 
expansion period allows for further manipulation of those T cells to enhance their 
antitumor capacity. Also, an overarching theme in ACT is that complete and 
durable responses are possible in patients who receive T cells capable of long-
term memory responses. We examined the impact of each element of the ACT 
regimen on the memory of T cells including how preconditioning influences 
memory and function, the advantage of employing IL-17 producing CD4+ T cells 
(Th17) cells with durable memory properties, and how to endow CD8+ T cells with 
improved memory capacity through blockade of the PI3K pathway. We 




of an activated innate immune system to improve the longevity of antitumor 
immunity and reduce the dose of total body irradiation (TBI). We also report that 
Th17 cells naturally express stem memory, which allows for expansion to high 
numbers of durable effectors and long-lasting immunity against tumors. Finally, 
peripheral T cells genetically redirected against tumors with chimeric antigen 
receptors (CAR T cells) can be enhanced by pharmaceutical blockade of PI3K 
endowing a durable memory phenotype that controls tumor after conventional CAR 
T cells fail. Thus, this dissertation provides evidence that at each step in the ACT 
protocol, T cells can be selected, or enhanced to exert powerful memory immunity 




Chapter 1: Harnessing Memory T cells to Improve Cancer Immunotherapy 
 
 
The challenge of metastatic disease  
While early detection and improved surgical techniques have greatly 
increased survival among patients with early stage/local cancers, gains against 
metastatic disease have been slow across cancer sites. This is well represented 
in patients with breast cancer, where early detection in stage 0 or 1 results in nearly 
100% survival at 5 years. Yet, patients diagnosed with stage 4 breast cancer have 
a 5 year survival rate of 22% (1). These rates translate into metastasis 
representing 90% of breast cancer related deaths. Additionally, adjuvant 
chemotherapy for localized breast cancer only prevents metastasis in about half 
of the patients who receive it (2). In the case of liver cancer, patients diagnosed 
with local disease have a 5 year survival rate of 30.5%, while the survival rate for 
patients diagnosed with distant disease is 3.1% (3). Melanoma follows the same 
trend with 90% survival at 10 years for stage 1 disease but only 10% survival at 10 
years for stage 4 (4).  
However, set against this bleak background, melanoma was also the 
impetus and origin of a novel group of therapies which act through the immune 
system (coined immunotherapies). These therapies are based on the theory that 
NK cells, CD8+ T cells, and CD4+ T cells reconnoiter the body seeking out and 




While still in its infancy, immunotherapy has already produced drastic increases in 
both objective and complete responses in patients who suffer from late-stage 
disease. 
 
Immunotherapy for melanoma: a model for treating metastatic disease  
For decades, the only approved treatment for metastatic melanoma was 
dacarbazine, a typical chemotherapy which extended survival for patients by a 
median of only 6.4 months (6). The past two decades have seen the development 
and FDA approval of promising new immunotherapies for the treatment of late-
stage melanoma with marked improvement in outcomes. Table 1-01 summarizes 
the objective and complete responses seen in recent trials of immunotherapies 
against metastatic melanoma in comparison to dacarbazine chemotherapy. 
 The most successful immunotherapies to date are based on manipulating 
tumor-reactive T cells. The earliest of these applied systemic treatment of the T 
cell growth factor interleukin-2. As an early proof of concept, this treatment had 
modest success in patients with renal carcinoma (7), and doubled the rate of 





Table 1-01. Treatment Response Rates in Patients with Metastatic Melanoma.  
A summary of the therapeutic outcomes of current therapies for metastatic 
melanoma including objective and complete responses based on the Response 




Checkpoint blockade takes the brakes off immunotherapy  
More recently, new understandings of how T cells are negatively regulated 
in the tumor led to the development of the checkpoint blockade antibodies anti-
CTLA-4 (Ipilimumab) and anti-PD-1 (Pembrolizumab and Nivolumab). These 
therapies share the underlying goal of “removing the brakes” or inhibitory signals 
that the T cells are receiving from the tumor microenvironment (9-11). 
Soon after its discovery, Cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) was described as a negative regulator of T cell activation that directly 
competed with CD28 for CD80 and CD86 on APCs (12). This led to in vivo studies 
with monoclonal antibodies that prevented CTLA-4 binding and resulted in tumor 
regression (13). More recent work suggests that not only does the antibody prevent 
effector T cell inhibition, but also breaks immune tolerance by causing the 
depletion of CTLA-4 expressing Tregs in the tumor (14). This therapy moved the 
field forward by doubling objective responses in comparison to systemic IL-2 (15). 
Programmed Death receptor 1 (PD-1) was originally discovered in T cells 
undergoing apoptosis (16). It was eventually linked with T cell inhibition and 
exhaustion in chronic viral infections (17, 18) and the tumor microenvironment (19). 
This led to early trials of the anti-PD-1 monoclonal antibody Nivolumab in 
melanoma, lung, colon and renal cancer with impressive outcomes (20). As single 
agents, CTLA-4 and PD-1 blockade produce unprecedented objective responses. 
But, in combination they have a particular therapeutic potency generating objective 




patient responses on checkpoint blockade therapy, anti-CTLA4 and anti-PDI 
therapy are quickly becoming approved to treat multiple malignancies (21). These 
findings in turn, have fueled excitement for immunotherapies within the oncology 
community.  
 
Adoptive cell therapy for cancer 
The first generation of adoptive cell therapy (ACT) for metastatic melanoma 
used peripheral lymphocytes grown in the presence of the patient’s tumor and IL-
2 termed “lymphokine activated killer cells” (22). This approach was followed by 
the first trials with tumor infiltrating lymphocytes (TIL). In TIL therapy, T cells are 
obtained directly from the patient’s tumor, and then in vitro selected for antitumor 
function, and expanded to large numbers before reinfusion into the patient (23-26). 
In these early TIL trials, 34% of patients achieved objective responses (25). Later 
studies enhanced the power of TIL based therapies with the addition of 
lymphodepleting regimens prior to adoptive T cell transfer. When patients received 
a preparative regimen of chemotherapeutics or chemo-radiation prior to receiving 
TIL and bolus IL-2 objective response rates rose to 54% (27). Since this time, a 
minimum of partial myeloablation (removal of most peripheral and some central 
hematopoietic cells) has been a staple in every ACT regimen. 
 While the objective response rates from ACT with chemo-radiation 
preconditioning was similar to the results of combined checkpoint blockade therapy 




even 30 years since treatment, 24% of patients in the preconditioning plus ACT 
trials still have complete responses; more than double the combined checkpoint 
therapy (24% vs. 11.5%) (15, 27). Thus, while ACT is more cumbersome than 
checkpoint blockade and not yet FDA approved for wide spread use, these clinical 
findings highlight the unique potential of ACT for long-term control of aggressive 
malignancies. 
 
Enriching tumor-reactive T cells from the periphery 
The tumor is an obvious first choice as a source of tumor-reactive T cells 
for ACT, but there are apparent limitations. In the early TIL trials, complications 
arose when T cells from some patients grew poorly or not at all. Additionally, not 
all patients who received T cell transfer responded to therapy indicating that not all 
TIL is equally potent (25). We know now that it is highly common for T cells within 
the tumor to be exhausted, and this exhaustion is imprinted in the genetics of those 
T cells (28). An additional complication is that TIL are not present in every cancer 
type, but usually only appear in those cancers with higher mutational burden (29).  
Thus, obtaining tumor-reactive T cells from the peripheral blood of patients 
is an attractive concept. Early work that described circulating lymphocytes specific 
for melanoma tumor antigens (30) led to different techniques for expanding 
antigen-specific T cells including using antigen peptide presenting APCs (usually 
autologous dendritic cells) (31), and nanoparticle artificial APCs (32). However, 




peripheral blood had similar rates of partial responses and complete remission as 
those in the TIL trials. (33, 34). Thus, obtaining a tumor antigen-specific cell is not 
enough, but successful treatment requires the expansion of tumor-reactive T cells 
capable of long-lived immunity. 
 
Endowing specificity through genetically engineering T cells  
Methods to generate rather than enrich antigen specific T cells for ACT 
include the genetic redirection of peripheral T cells to express either T cell 
receptors (TCRs) (35-37) or chimeric antigen receptors (CARs) (38-41). The 
benefit of genetic receptor redirection is it allows the selection of T cells capable 
of exerting a potent and durable immune response (ie. not exhausted). However, 
transgenic TCRs are still limited to HLA restriction making them not available for 
every patient. Further complicating the problem, HLA restriction also requires that 
a mutation occur within a peptide sequence that can be presented by MHC (42).  
CARs bypass the requirement of MHC antigen presentation by fusing the 
intracellular signaling domain of the TCR receptor complex (CD3), with the 
antigen binding fragrment (Fab) of an antibody specific for a surface protein highly 
expressed on a tumor (38). Thus, in an MHC-independent manner, a CAR-T cell 
can recognize a tumor expressing the cognate protein in any patient with that 
cancer (for instanced CD19+ blood malignancies). Additionally, CARs can now also 
directly address the issue of improving the potency of the T cell, with the second 




ligands (42). Different costimulatory signals (i.e. CD28 vs. ICOS vs. 4-1BB) endow 
different metabolic, functional, and memory capacities in the cells, and thus T cells 
can be engineered with a CAR that fits the goal of the therapy (43). Already, CAR-
T cells have proven very effective in clinical trials against lymphoma (39, 40) and 
multiple CARs are being developed against common antigens in solid tumors 
including mesothelin, fibroblast activating protein, and Muc-1 (38, 44, 45).  
Yet, no matter whether tumor-reactive T cells are enriched or engineered 
from TIL or peripheral blood, we and other cancer immunologists have identified 
three major elements common for successful ACT therapy: 1) lymphodepletion of 
the patient to break immunological tolerance and permit persistence of infused T 
cells, 2) the quality and fitness of the T cell selected for therapy, and 3) the optimal 
expansion of those T cells ex vivo to improve antigen specificity, function, and 
memory. Additionally, evidence mounts that using a T cell for ACT with a less 
differentiated phenotype improves outcomes through long-lived memory immune 
responses (46-50). Preserving or inducing “memory” in tumor-reactive T cells 




   
Figure 1-01. Improving ACT therapeutic outcomes by inducing memory.  
Strategic enhancements of memory within each element of ACT to provide 




The importance of memory: persistent and stronger antitumor responses  
Immune memory was first recognized in the context of vaccines which were 
able to endow long-lived (including life-long) protection against a pathogen (51). 
The concept of memory within the adaptive immune system is rapidly evolving but 
still contains at its core the concept of a B or T cell which persists after the initial 
immune response and can mount repetitive responses against an antigen 
throughout the host’s lifetime (52). T cell memory is also important in tumor 
immunity as patients in ACT clinical trials whose transferred T cells persisted 
longer and at higher numbers had better responses and outcomes than those with 
fewer, short-lived T cells (53). Also, further studies found that persistent antitumor 
immunity was carried out by tumor-reactive T cells with longer telomere length 
which are maintained by self-renewing cells (54, 55). Thus, it appeared that certain 
subsets of T cells were capable of self-renewal and were responsible for long-term 
immune protection (56, 57).   
 
The hallmark memory receptors CD62L and CCR7  
Memory T cells were first described as two groups distinct from naïve T cells 
and were defined by location, function and expression of the surface markers 
CD62L and CCR7 (58). At the time, naïve T cells were known to use CD62L and 
CCR7 receptors to enter lymphoid tissues. Yet, another subset of CD62L+ and 
CCR7+ T cells was found in the lymphoid tissue which unlike naïve cells, 




central memory T cells because of their location in lymphoid tissue and their 
memory-like capacity to rapidly activate APCs. Another subset mainly found in the 
periphery expressed little CD62L and CCR7, but were highly functional with the 
ability to rapidly produce inflammatory cytokines (such as IFN-) upon activation. 
These were thus called effector memory T cells. Importantly, CD62L and CCR7 
expression by naïve and central memory cells declined throughout culture, and 
were never regained by effector memory cells. Therefore, this study also proposed 
that at least in vitro, there was a continuum of differentiation from naïve to central 
memory to effector memory to effector T cell. (58).  
While the trajectory of in vivo development of memory and effector T cells 
remains highly debated (59), studies in many ACT models corroborate the theory 
that naïve cells give rise to central memory cells, followed by effector memory and 
effector cells in vitro following activation (46, 48, 60, 61). Additionally, these studies 
reveal a strong correlation between less differentiated memory T cells (CD62Lhi or 
CCR7hi T cells) and better antitumor treatment outcome (50, 62), with loss of 
antitumor efficacy associated with terminal effector differentiation (46-50). Thus, 
strategies to limit T cell maturation and to preserve long-lived memory is a critical 
goal in the field of cancer immunotherapy.  
 
Stem memory T cells exert durable immune responses against tumor  
The first report of stem cell-like T cells described a sub-population of 




were able to generate all other memory and effector T cell subsets and prolong 
GVHD (63). Further studies showed that these cells were a distinct memory subset 
that actively signals through -catenin (64). Human T cells with the same active 
Wnt signaling also gave rise to all other memory and effector lineages including 
central memory and were dubbed stem memory T cells (Tscm) (60). Importantly, 
when compared head-to-head with other memory subsets, stem memory T cells 
exerted better control of tumor (60). Additionally, pharmaceutical inhibition of -
catenin degradation by GSK3 endowed T cells with the phenotype of Tscm cells. 
These findings indicate that active Wnt signaling is not only an important indicator 
of a less differentiated T cell, but may be an important driver of durable T cell 
memory and superior antitumor potency. 
 
Homeostatic gamma chain cytokines in T cell memory 
IL-2, IL-7, and IL-15 belong to a family of cytokines whose receptors share 
a common gamma chain. These cytokines also have shared function in promoting 
the proliferation, preservation and persistence of T cells (and other cells like NK 
cells). They are therefore often referred to as “homeostatic cytokines” for their 
importance in maintaining these populations in the body (65).  
Early clinical trials in cancer explored the role of IL-2 to enhance 
endogenous tumor-reactive T cells. This therapy was successful at clearing tumor 
in some patients but its effects on tumor growth was modest in most individuals (7, 




boost CD8+ T cell proliferation after transfer through systemic administration (24, 
25). Yet, IL-2 has limitations as it mediates substantial toxicities in some patients 
(66), and terminally differentiates the CD8+ T cells (67) rendering the therapy less 
effective (46).  
Like IL-2, IL-15 also signals through both the IL-2 and gamma chain 
receptors. Yet, IL-15 signaling supports the proliferation and preservation of 
memory T cells and NK cells in vivo (68) and preserves a less differentiated 
phenotype of T cells during in vitro expansion (69). It remains unclear why 
signaling from IL-2 causes effector differentiation while IL-15 signaling through the 
same two receptor chains uncouples proliferation and differentiation. The most 
recent theory is that the differential signaling might be due to differences in ligand-
receptor complex stability (70). Despite IL-15’s capacity to preserve memory 
during proliferation, IL-2 is still commonly used to expand T cells for ACT clinical 
trial protocols (33, 50, 71) mostly due to industry restraints (65).  
Both naïve and central memory T cells express IL-7 receptor alpha (CD127) 
and IL-7 is important in maintaining these cells in vivo (72). IL-7 also augments the 
engraftment and prolonged antitumor activity of adoptively transferred IL-12 
primed CD8+ T cells in mice (73). Under normal conditions, IL-7 is not a strong 
proliferative signal. However, in cases of immune depletion, the per-cell signal of 
IL-7 can be strong enough to induce proliferation even in antigen naïve T cells (74). 




contribute to a higher yield of cells by preventing apoptosis of memory cells, and 
thus synergize with other gamma-chain signals (65, 75).  
IL-21 induces many signals in T cells. IL-21 prevents terminal differentiation 
of CD8+ T cells in a similar fashion to IL-15. This is in part due to blockade of 
signaling downstream of IL-2 (76). In comparative studies, IL-21 supports the 
antitumor immunity of CD8+ T cells better than the other homeostatic cytokines 
(77). This does not appear to be due to a proliferative signal, although it can 
synergize with other gamma-chain cytokines (75). Rather, IL-21 appears to 
support the inflammatory nature of mature T cells, including acting as an 
alternative pathway to induce inflammatory Th17 cells (77, 78). 
The vital role of homeostatic cytokines to T cell growth and functional 
augmentation makes them central to ACT protocols. Methods for increasing time 
and strength of gamma-chain signals include the complexing of IL-2 with 
antibodies (79) and IL-15 with its alpha receptor (80).  Yet, one of the most potent 
means of improving homeostatic cytokine availability for ACT is through host 
preconditioning with either chemotherapy or irradiation. This has two major 
benefits: 1) it induces homeostatic cytokine secretion (81) and 2), it removes 
endogenous immune cells which would compete for these elevated cytokines (82).  
 
The requirement for non-myeloablative preconditioning in ACT  
Since the early TIL clinical trials, multiple studies have increased our 




prior to T cell transfusion. In these studies, three important benefits of 
lymphodepletion are described: 1) the removal of immunosuppressive cells 
including Tregs (83), 2) depletion of host immune cells which compete for 
necessary homeostatic cytokines (known as cytokine sinks) (82), and 3) activation 
of the innate immune system which in turn enhances the antitumor response of the 
infused T cells (84). Thus, preconditioning improves the capacity of transferred 
cells to maintain a memory response to the tumor and exert long-term control by 
increasing the persistence of donor cells, as well as their function. The marked 
increase in complete responses between TIL clinical trials which used 
lymphodepleting regimens and those without provides evidence that 
preconditioning not only accentuates the initial immune responses, but also 
increases the odds that T cell immunity will be long-lived (25, 27).  
 
IL-12 signaling from irradiated dendritic cells enhances function and 
prolongs the antitumor response of Tc17 cells 
In chapter 1, we explored the role of preconditioning on the memory and 
function of transferred CD8+ T cells. Since previous work found that ex vivo priming 
of CD8+ T cells with IL-12 improved their persistence (73), we hypothesized that 
IL-12 signaling following TBI activation of innate immune cells improved antitumor 
response by increasing T cell persistence. Since IL-17 producing CD4+ T cells 
(Th17 cells) have a stem memory phenotype (85), we further hypothesized that 




T cell with memory features that would synergize with lymphodepletion. Indeed, 
we reported direct correlation with the strength of preconditioning TBI and the 
antitumor efficacy of both non-polarized CD8+ T cells (Tc0 cells) and Tc17 cells. 
Additionally, the potentiating effects of lymphodepletion were stronger on Tc17 
antitumor responses than Tc0.  
We found that TBI increased IL-12 and IL-23 secretion by activated dendritic 
cells, and that neutralizing IL-12 in irradiated mice greatly hampered the antitumor 
response by infused Tc17 cells.  Enhancement of Tc17 antitumor immunity by IL-
12 signaling appeared to be due to a change in function from IL-17 production to 
IFN production and higher infiltration of Tc17 cells into the tumor to similar levels 
as in fully myeloablated mice. Additionally, TBI increased the memory capacity of 
donor Tc17 cells to secrete cytokines upon antigen reintroduction at memory 
timepoints. Interestingly, this was not due to a change in memory phenotype as IL-
12 only increased CD62L on the surface of Tc0 cells, not on Tc17 cells which 
expressed nominal levels of CD62L.  
Additionally, IL-12 priming ex vivo lowered the requirement for TBI. When 
coupled with systemic administration of IL-12 after T cell transfer, IL-12 priming of 
Tc17 cells caused durable remission of tumors without preconditioning. These 
results underline the importance of both preconditioning and resultant IL-12 
signaling in enhancing the capacity and durability of CD8+ T cell antitumor 




as type 17 T cells could ensure optimal synergy between the T cell and the 
preconditioned environment.  
 
Successful adoptive cell therapy depends on high numbers of potent tumor 
reactive T cells  
A key parameter to preparation of T cells for adoptive cell therapy is 
expansion to large numbers. Current clinical trials require expansion of tumor-
reactive T cells to upwards of 6x1010 T cells to ensure the patient receives an 
effective dose (42, 49, 86). While necessary, these cell numbers come at a heavy 
cost, as CD8+ T cells lose their antitumor potency when they differentiate during in 
vitro expansion (46). Similarly, human TILs that undergo shorter expansion and 
thus are less differentiated in vitro persist longer in the host, which is linked with 
greater tumor regression (53-55, 87).  
 
Th17 cells are potent stem-memory effector cells 
To answer the dilemma of generating high yields of less differentiated 
tumor-reactive T cells, we sought after a T cell subset capable of rapid proliferation 
without loss of memory capacity. Th17 cells are increasingly implicated in a wide 
array of autoimmune diseases and are characterized as highly inflammatory long-
lived effectors (88). As a proposed mechanism of their longevity, Th17 cells have 
active Wnt/-catenin signaling (85), which is normally only found in epithelial and 




signaling in Th17 cells may be due to the cytokine milieu which programs the Th17 
cell phenotype namely: TGF, IL-6, IL-21, and IL-1. Of these, IL-6, IL-21 and IL-
1 are closely tied to stem cell signaling in both cancers and hematopoietic stem 
cells. For example, STAT3 downstream of IL-6 is implicated in active stem cell 
signaling in pluripotent stem cells (89) and is an important inhibitor of apoptosis in 
T cells (90). IL-6 also potentiates IL-21 signaling (91), which itself enhances an 
inflammatory phenotype in Th17 cells (78). IL-21 has also been shown to improve 
the memory and resultant antitumor efficacy of tumor-reactive T cells expanded in 
vitro (76). IL-1 also plays a role in both Th17 polarization and Wnt signaling in 
certain cancers (92). Consequently, Th17 cells are the recipients of multiple 
stemness signals amenable to instilling durable memory. 
Since current efforts to minimize terminal differentiation of CD8+ T cells with 
shorter in vitro expansion have had limited success (87), we propose the 
employment of Th17 cells which are known to mediate long-lived antitumor 
responses (93-95). Additionally, even though Th17 cells are thought to only play 
the traditional role of a  CD4+ helper T cell, studies show that beyond their ability 
to potentiate CD8+ T cell responses (96-98), CD4+ T cells are capable of directly 
lysing targets on their own (99, 100). In either case, Th17 cells appear to combine 
potent effector function (93) with the molecular signature of Tscm cells (60, 85). 
This makes Th17 cells particularly attractive in the context of ex vivo expansion 




retain their antitumor capacity even after long term ex vivo expansion to large 
numbers.  
 
Th17 cells mediate durable memory immunity after long-term ex vivo 
expansion  
In chapter 2, we tested the durability of Th17 cells to produce antitumor 
responses by expanding Th17 cells in vitro for one to three weeks. We discovered 
that these differentially expanded Th17 cells had comparable antitumor capacity 
on a per cell basis, exerting equal control of established melanomas in mice. 
Further investigation showed that while Th17 cells underwent plastic conversion 
from IL-17 production to IFN during culture, they exhibited a stable memory 
phenotype of Tscm cells with preserved expression of nuclear Tcf7. This correlated 
with equivalent capacity to persist in the host no matter the length of expansion. 
Comparison to Th1 cells which did not retain antitumor capacity during expansion 
showed that Th17 cells were resistant to both apoptosis and senescence during 
expansion. The importance of preserved potency over expansion was further 
revealed when we could only eradicate large, intractable tumors using the full yield 
of Th17 cells expanded for two or three weeks, while the yield of Th17 cells after 
one week was not sufficient. Treatment with high numbers of potent Th17 cells 
also resulted in long-lasting immunity. Mice receiving these Th17 cells were 
protected from multiple tumor re-challenges including psuedometastases in the 




towards clinical translation, we also demonstrated that CAR-T cells obtained from 
peripheral blood had an undiminished capacity to clear tumors at the end of two 
weeks of expansion if polarized to be Th17 cells but not as Th1 cells.  
 
Pharmaceutical induction/preservation of memory in T cells  
Another promising method for enhancing the memory of tumor-reactive T 
cells is through pharmaceutical manipulation. This has multiple benefits including 
simplicity of preparation when compared to bead or fluorescence (FACS) based 
sorting of memory T cells. Also, using the drugs solely ex vivo prevents potential 
drug-related toxicities to the patient. A frontrunner in this field was the treatment of 
T cells with TWS119 which blocks the degredation of -catenin, allowing it to enter 
the nucleus and signal. This treatment endowed the cells with the same phenotype 
as Tscm cells which were shown to be highly therapeutic (60, 64). A major benefit 
from this drug priming strategy was increasing the yield of Tscm cells far beyond 
what could be collected through sorting these cells from peripheral blood.  
Many studies indicate that effector and memory T cells depend on different 
metabolic pathways. Early work noticed that activated T cells abruptly increased  
aerobic glycolysis to meet the energy and metabolite demands of proliferation and 
function (101, 102), thus a recent study showed that blocking glucose uptake by T 
cells with a small molecule inhibitor resulted in less differentiated cells (103). In 
contrast, memory T cells depend more on mTOR dependent oxidative pathways 




Rapamycin preferentially expanded memory CD8+ T cells with augmented 
oxidative phosphorylation (106). Similarly, a recent article found that just 
pharmaceutical induction of mitochondrial networking was sufficient to endow the 
T cells with the antitumor efficacy of memory T cells (107). Interestingly, these 
treatment protocols use reversible inhibitors and yet the effects of these drugs on 
the cells are stable. This suggests the tantalizing possibility that transient drug 
exposure may lead to fundamental genetic, or epigenetic changes that lock in a 
memory phenotype. 
 
T cell memory is enhanced by inhibiting the PI3KAKT signaling pathway  
The PI3K/AKT axis plays a central role in shaping a T cell’s phenotype. T 
cells express all three class 1A catalytic subunits of PI3K (p110and ), but 
p110 is almost exclusively used downstream of the TCR and costimulatory 
molecules (108, 109). Thus P110mediates the classical activation of T cells with 
resultant proliferation, cytokine production, and cytotoxic function (110). 
Additionally, PI3K signaling provides protection of maturing T cells from apoptosis 
within the thymus (111) and prevents apoptosis post antigen recognition (112).  
This pathway is also important for developing CD8+ T cell memory (113).  
Individuals who either have a mutated p110 subunit that is constitutively active, 
or a loss of function mutation in the p85 inhibitory subunit, suffer from persistent 




(including splenomegaly), lymphomas and autoimmunity (114). In these patients, 
CD8+ T cells rapidly divide and terminally differentiate expressing markers of 
exhaustion, which may explain their susceptibility to viral infection (115). 
Interestingly, while loss of the P110 subunit results in impaired proliferation and 
cytokine production by mouse T cells in Listeria infection (116), it results in 
improved clearance of infection with little impact the generation of antigen specific 
memory cells (117, 118). However, the improved primary response against acute 
infection appeared to be due to impairment of Treg function, and in a subsequent 
study the reduced numbers of memory T cells following a primary infection leads 
to impaired memory responses (119). In all these reports, it appears that chronic 
loss of PI3K signaling results in poor immunity by a reduced number of impaired 
CD8+ T cells. In contrast, two studies found that blocking AKT with the reversible 
inhibitor AKT VIII (or AKTi) enhanced the memory and antitumor capacity of T cells 
in the setting of allograft stem cell transplant for multiple myeloma (120) and 
melanoma TIL based ACT (121). Thus, it appears that genetic knockout of 
PI3K/AKT signaling does not affect the immune capacity of T cells in the same way 
that reversible drug inhibition does. 
While PI3K is almost always studied in the context of activating AKT, it has 
multiple other downstream targets as well. PI3K is one of the first enzymes 
activated by not only the TCR, but other tyrosine receptor kinases, and GPCRs as 
well. It’s implicated in cross-regulation with multiple kinase families including the 




(which is the acting kinase on AKT) is considered the “master kinase” of the AGC 
family as it phosphorylates protein kinase A, G, and C families as well as a variety 
of lesser known kinases (125). Thus, we expected that blockade of PI3K would 
not only induce a T cell memory phenotype similar to what AKT inhibition 
generates, but would do so more potently. We therefore tested whether inhibiting 
the p110 subunit of PI3K compared to direct AKT inhibition would induce an even 
stronger memory phenotype and endow a more potent antitumor capacity in T 
cells. 
 
Idelalisib (CAL-101): a potent drug with great potential in ACT  
Our understanding of the PI3K/AKT axis is due largely to studies in human 
cancers where it is also canonically associated with proliferation and resultant 
regulation of metabolism, cell cycle, and apoptosis (126). As a major target of drug 
discovery research, this pathway now has multiple potent and specific inhibitors 
(127). Among these is Idelalisib (CAL-101) which was developed to specifically 
block P110 signaling in hematologic malignancies. After studies showed the drug 
was highly effective in treating acute myelocytic leukemia (128), acute 
promyelocytic leukemia (129), and refractory CLL and non-hodgkin lymphoma 
(130), the FDA approved Idelalesib for use in a variety of blood cancers.  
However, at the same time, evidence was mounting that along with clearing 
B cell malignancies, this drug also depleted Tregs causing serious and fatal cases 




warning and relegation of Idelalisib to 3rd or 4th line treatment. Yet, among all these 
studies of its effects on both the cancer and peripheral tolerance, its impact on 
effector T cells remains poorly understood. Thus, if the memory induced by AKTi 
inhibition could be translated to PI3K blockade, then an already FDA approved 
and powerful drug remained available for enhancing tumor-reactive T cells in the 
safety of ex vivo T cell preparation. 
 
Imprinting memory in tumor-reactive T cells via blockade of P110  
In chapter 3, we compared blockade of P110 and AKT in both murine 
effector CD8+ T cells from pmel-1 mice and human peripheral CD3+ T cells. In 
pmel-1 cells, AKT blockade increased the frequency of CD62L expressing cells 
and a predominant CD44hiCD62Lhi phenotype as expected. However, P110 
blockade increased CD62L on the cells to a higher extent than AKT blockade, and 
lowered CD44 expression lending a phenotype to the cells normally associated 
with naïve T cells. P110 blockade also induced the highest expression of CD127, 
indicating higher responsiveness to IL-7. CAL-101 treated T cells persisted at the 
highest levels compared to AKT blocked and untreated T cells one week after 
infusion. Thus, while AKT blockade marginally improved tumor control over vehicle 
treated mice, blocking P110 signaling greatly enhanced tumor control. 
We saw similar phenotypic changes in human CD3+ T cells with increased 
levels of CCR7 and CD127 after P110 blockade. Interestingly, we also noticed 




blockade versus AKT blockade and vehicle. When transduced with a CAR specific 
for mesothelin tumor antigen, CAL-101 primed T cells controlled tumors longer 
than vehicle and AKTi treated CAR-T cells.  
It remained unclear whether increased CD62L, CCR7, and CD127 from 
P110 blockade were driving the improved antitumor response, or merely markers 
of a more potent T cell. We therefore tested the importance of the memory markers 
CD62L and CD127 in the memory response of these T cells against tumor. We 
found that while CD62L+ T cells from vehicle treated T cells looked phenotypically 
like CAL-101 primed T cells, they could not match the antitumor potency of CAL-
101 primed cells and were no more effective than unsorted bulk T cells. Despite 
neutralization of IL-7 for two weeks after T cell transfer, CAL-101 primed cells 
engrafted and controlled tumor similar to CAL-101 primed T cells in isotype control 
mice. Thus, while our understanding of T cell memory started with recognizing 
memory T cells by expression of CD62L, CCR7, and CD127, we are finding that 
these molecules do not fully explain why memory T cells deliver stronger antitumor 
responses. We posit that other pathways such as proteins transcribed by the -
catenin pathway may be more crucial drivers of T cell durability and potency. 
 Through the last three decades, ACT has grown from a little-known therapy 
conducted at one research center, to a worldwide effort to direct T cells against a 
variety of malignancies. As our understanding of basic principles of T cell immune 
responses increases, our ability to manipulate the T cells to exert stronger 




endorse multiple methods for preparing a more effective cellular product for ACT 
including the use of preconditioning, selecting stem memory effector cells such as 






Chapter 2: Materials and Methods 
 
 
Mice and Tumor lines 
Mice. C57BL/6J (B6), CD45.1 congenic B6, TRP-1 and pmel-1/Thy1.1 TCR 
transgenic mice and NOD/scid/gamma chain knock out (NSG) mice were 
purchased from Jackson Laboratories and housed and bred in the Medical 
University of South Carolina Hollings Cancer Center (MUSC, Charleston, SC) 
comparative medicine department. NSG mice were housed under specific 
pathogen-free conditions in microisolator cages and given autoclaved food and 
acidified water.  Housing and experiments were conducted in accordance with 
MUSC’s Institutional Animal Care and Use Committee’s (IACUC) procedures.  
Tumor Lines. B16F10 (H-2b) melanoma tumor, gift of the Nicholas Restifo 
lab at NCI surgery branch was maintained in culture media (RPMI 1640 w/ L-
glutamine, 10% FBS, 1% Pen/strep, NEAA, and Na Pyruvate, and 0.1% BME and 
Hepes). M108 xenograft tumors were a gift from the June lab at the University of 
Pennsylvania. M108 were cultured and engrafted as described previously (38).  
 
Cell preparation and culture 
Pmel-1 CD8+ T cells. Splenocytes were harvested from Vβ13+ Pmel-




stimulated with 1μM human gp10025-33 peptide (KVPRNQDWL) in 48 well plates 
(1 mL media containing 1 × 106 cells/well). CD8+ T cells polarized at activation 
towards Tc0 (100 IU/mL rhIL-2) or Tc17 (100 ng/mL rhIL-6, 30 ng/mL rhTGF-, 10 
μg/mL anti-mouse IL-4, 10 μg/mL, anti-mouse IFN-). If T cells were primed, 
priming occurred on day 1 or 2 by adding rmIL-12 (40 ng/mL) or rmIL-23 (60 ng/mL) 
where indicated. Cells were split every day starting from day 3 and Tc17 cells 
supplemented with 20 IU/mL rhIL-2 while Tc0 cells continue to be expanded with 
100 IU/mL rhIL-2. For drug priming experiments, starting 3 hours after initial 
activation, cells were treated with either DMSO vehicle, AKT inhibitor VIII (AKTi) 
at 1M (Calbiochem), or CAL-101 at 10M (Selleckchem). Cells were 
supplemented with culture media containing 100 IU rhIL-2/mL and vehicle or drug 
when expanded. Where indicated, CD8+ T cell cultures were in vitro activated with 
feeder cells and peptide 12 hours before transfer as described (131). 
 TRP-1 CD4+ T cells: TRP-1 splenocytes were activated using 10 Gy 
irradiated B6 splenocytes (feeder cells) pulsed with 1M TRP-1 peptide and 
polarized to a Th17 phenotype at 3e6 cells/2 mL of cell media in one well of a 24 
well plate with the following cocktail: 100 ng/mL rhIL-6 (NIH repository), 100 ng/mL 
rhIL-21 (Shenandoah), 30 ng/mL rhTGF1 (Biolegend), 10 ng/mL rhIL-1 (NIH 
Repository), 10g/mL each of anti-mIFNclone XMG1.2, anti-mIL-4 clone 11B11, 
and anti-mIL-2 clone JES6-1A12 (BioXcell). Th1 polarization occurred under 




rmIL-12 (Shenandoah), 100 IU/mL rhIL-2 (NIH repository), and 10g/mL anti-mIL-
4 clone 11B11 (BioXcell). Cultured cells were supplemented with new media 
containing 100 IU/mL rhIL-2 (NIH repository) throughout expansion, then 
cryopreserved at time-points indicated in 10% DMSO in FBS. One day before 
transfer, cells were thawed and plated in cell media overnight and then transferred 
into mice.  
Human Normal Donor Peripheral T cells: To generate mesothelin-specific 
CAR-Th17 cells, human CD4+ T cells were activated with CD3/CD28/ICOS coated 
beads and programmed to a Th17 or Th1 phenotype and then transduced with a 
chimeric antigen receptor (CAR) that contained either an anti-mesothelin, or anti-
CD19 single-chain variable fragment (scFv) fusion protein containing the T cell 
receptor  (TCR) signaling domain and 4-1BB that was generated as described 
previously (38) (gifts from the June lab) . CD4+ T cells were polarized to Th17 
phenotype as follows: 10 ng/mL rhIL-1, 10 ng/mL rhIL-6, 20 ng/mL rhIL-23, 10 
g/mL anti-hIL-4 clone 11B11, and anti-hIFN clone H22 (eBioscience). 
Experiments were conducted with fetal calf serum containing endogenous sources 
of TGF-. Th1 cells were polarized as follows: 10 g/mL rhIL-12 and 100 IU/mL 
rhIL-2. Cell cultures were maintained with 100IU/mL of rhIL-2 and cells were 
expanded for up to two weeks. Likewise, human CD8+ T cells were activated with 
CD3/CD28/ICOS beads and redirected with either the anti-meso or anti-CD19 




prepared via negative bead selection (Dynal) from peripheral blood lymphocytes 
and activated using CD3/CD28 beads (Gibco) with 100 IU rhIL-2/mL and either 
DMSO vehicle or drug. On day 2 of culture, T cells were engineered the anti-
mesothelin CAR. IL-2 and vehicle or drug were administered in fresh CM as T cells 
were expanded throughout culture. 
 
Adoptive cell therapy 
B6 mice were given 4.5e5 B16F10 cells subcutaneously between 5-12 days 
before ACT. One day before therapy, mice received nonmyeloablative 5 Gy total 
body irradiation (non-myeloablative) or 9 Gy (myeloablative) TBI. HSCs, given to 
mice treated with 9 Gy TBI, were extracted from the bone marrow by lineage 
depletion with streptavidin-coated magnetic beads (Dynabeads M-280 
Streptavidin; Dynal Biotech) against biotin-labeled antibodies ( T cell receptor, 
 T cell receptor, CD4, CD8a, NK1.1, Gr-1, B220, Ter-119, CD2, CD11b; BD 
Biosciences) followed by a c-kit enrichment with CD117 Microbeads (Miltenyi 
Biotec) and cultured for 18 hours in 10% DMEM with 50ng rmIL-3, 500ng rmIL-6, 
and 500ng rmCSF (PeproTech); 1 × 105 cells were administered one day post-
irradiation. The mice were treated via adoptive transfer of T cells infused via tail 
vein. In the experiments with pmel-1 CD8+ T cells, T cells were in vitro activated 
when indicated, then starting on the day of ACT, mice were given intraperitoneal 




was prepared at 1.5g rhIL-2 (NIH) and 7.5g anti-IL-2 antibody (clone JES6-1A12 
BioXCell) per mouse and administered via intraperitoneal injections on days 0, 2, 
and 4 of treatment. Serial tumor measurements were obtained and tumor area was 
calculated by multiplying the perpendicular diameters, then plotted. 
NSG mice were given 5-6e6 M108 suspended in matrigel subcutaneously 
as previously described (38). Tumors established for 40-50 days prior to adoptive 
therapy. In all experiments, mice were randomized to treatment groups and tumor 
burden was monitored in blinded fashion using perpendicular caliper 
measurements and reported as tumor area (mm2). 
 
In vivo cytokine neutralization 
IL-12 family cytokine neutralization. Neutralizing antibodies against murine 
IL-12p35 (MMp35A1.6; eBioscience) or IL-23p19 (AF1619; R&D systems) were 
administered beginning at 0 hours post-transfer, via intraperitoneal injection with 
100μg neutralizing antibodies and repeated every other day for 5 cycles. The 
control group received isotype-matched antibody. 
CD8+ T cell depletion. mice received weekly intraperitoneal injections with 
100g either anti-CD8 depleting antibody clone 53-6.72 or Isotype control clone 
2A3 (BioXcell) beginning the day before adoptive cell transfer and continuing 




IL-7 cytokine neutralization. Mice received 200g of either IL-7 neutralizing 
antibody (clone M25) or IgG2b isotype (clone MPC-11) (BioXCell) on days 0, 3, 5, 
8, 12, and 17 of treatment via intraperitoneal injection as previously described (73). 
 
Vitiligo Autoimmunity Score.  
Severity of autoimmune vitiligo was scored after the phenotype stabilized. 
Depigmentation was rated based on a graduated scale from 1 to 5 with 1 being no 
loss of pigment (all black) and 5 being total loss of pigment (all white). Mice were 
scored in blinded fashion in triplicate. 
 
Tissue Distribution Analysis 
Spleens from treated mice were harvested and mechanically disrupted 
using the tip of a syringe plunger. Cells were filtered through a wire mesh, red 
blood cells lysed with RBC lysis buffer (Biolegend), and then re-suspended in cell 
media for analysis. Eyes and tumors were sectioned, then incubated in 1 mg/mL 
collagenase type II (life technologies) at 37°C for one hour. Disgested tissue was 
filtered, re-suspended in cell media and plated for assay. Before probing with 
antibodies, FC block (Biolegend) was applied to cells at 1 g/100 L. Cell 





Flow Cytometry, in situ flow cytometry, and ELISA 
Flow Cytometry. Surface stains were performed in 2% FBS in PBS. 
Intracellular staining of cytokines and transcription factor stains occurred after 
surface staining, intracellular staining with antibodies was performed according to 
the manufacturer’s protocol using Fix and Perm buffers (Biolegend). For 
intracellular stains, cultured cells were restimulated with either 1μM human 
gp10025-33 peptide for pmel-1 cells or TRP-1 peptide for TRP-1 cells using 
irradiated splenocytes as antigen presenting cells (1:5 T celll:Irradiated 
splenocytes) from C57BL/6 mice for 5 hours or generically restimulated with PMA 
and Ionomycin. Monensin (Biolegend) was added after one hour of stimulation with 
the peptide. Data were acquired on FACSVerse or Accuri (BD Biosciences). All 
data were analyzed with FlowJo software (Tree Star).  
Antibodies used: anti-mCD3-efluor450 clone 17A2, anti-h/mRort-PE 
clone AFKJS-9 (eBioscience), anti-m4-1BB-Biotin clone 17B5, anti-m4-1BBL-PE 
clone TKS-1, anti-hCCR6-PECy7 clone G034E3, anti-hCCR10-PE clone 6588-5, 
anti-hCD4-APCCy7 OKT4, anti-mCD8-PerCPCy5.5 clone 53-6.7, anti-mCD8-
PECy7 clone YTS156.7.7, anti-hCD8-PerCPCy5.5 clone SK1, anti-mCD25-FITC 
clone 7D4, anti-hCD25-APCCy7 clone BC96, anti-mCD27-PECy7 clone LG.3A10, 
anti-mCD28-PerCPCy5.5 clone 37.51, anti-h/mCD44-PerCPCy5.5 clone IM7, anti-
hCD45RO-APC clone UCHL1, anti-hCD62L-FITC clone DREG-56, anti-mCD69-
PECy7 clone HI.2F3, anti-mCD70-APC clone FR70, anti-mCD127-PE/V450 




anti-mF4/80-PECy7 clone BM8, anti-mH-2Db-PE clone 28-14-8, anti-mICOSL-PE 
clone HK5.3, anti-mIFN--BV421 clone XMG1.2, anti-mIL-10-FITC clone JESF-
16E3, anti-mIL-17A-PE clone TCII-18H10.1, anti-mLAG3-PE clone C9B7W, anti-
mLy6C-APCCy7 HK1.4, anti-mLy6G-FITC clone 1A8, anti-mOX40L-PerCPCy5.5 
clone RM134L, anti-mPD1-PerCPCy5.5 clone 29F.1A12, Streptavidin-BV 421, 
anti-mTIM3-PE clone B8.2C12, anti-hTIM3-PE clone F38-2E2, anti-mTNF--
PECy7 clone MP6-XT22, and, anti-mV13-PE/APC clone MR12-3/MR12-4 
(Biolegend), anti-hCCR5-V450 clone 2D7/CCR5, anti-mCCR7-PE clone 4B12, 
anti-hCCR7-PECy7 clone CCR7, anti-hCD4-APCH7 clone RPA-T4, anti-mCD4-
APC/PE/APCCy7 clone RM4-5, anti-hCD8-V450 clone RPA-T8, anti-mCD11b-PE 
clone M1/70, anti-mCD11c-APC clone HL3, anti-mCD45.1-APCCy7 clone A20, 
anti-mCD45.2-V500 clone 104, anti-mCD62L-APC clone MEL-14, anti-mCD80-
FITC clone 16-10A1, anti-mCD86-PE clone GL1, anti-mCD95-PECy7 clone Jo2, 
anti-mICOS-Biotin clone 7E.17G9, anti-mKLRG1-APC/V450 clone 2F1, anti-
mNK1.1-PE clone PK136, anti-hPD1-FITC clone M1H4, anti-h/mTbet-AF647 
clone 4B10, anti-mV14-FITC clone 14-2 (BD). Cell viability assessed via Zombie 
Live/Dead Stain (biolegend). 
In situ flow cytometry. Apoptosis assays were performed with Biolegend’s 
FITC Annexin V Apoptosis Detection Kit with PI, per manufacturer’s instructions. 
Telomere length was measured using the Telomere PNA Kit/FITC via Flow (Dako) 




ELISA. ELISAs for IL-17A, IL-17F, IL-22, IFN, and IL-2 were performed 
using DuoSet ELISA kits (R&D) per manufacturer’s instructions and read on a 
thermoscan spectrophotometer (Thermofisher). 
 
In vivo Cytotoxic Assay  
C57BL/6 splenocytes were incubated with either TRP peptide or OTII 
peptide then labeled with a low level (0.5M) or high level (5M) of cell trace violet 
(CTV) (Thermo Fisher Scientific) respectively. TRP and OTII-pulsed splenocytes 
were mixed at equal ratio then injected intravenously into mice previously treated 
with Th17 cells or untreated control mice. After 12 hours, spleens were harvested 
from mice and the ability of donor cells to lyse TRP-pulsed splenocytes vs. OTII-
pulsed splenocytes was assessed via flow and reported as % specific lysis using 
the following equation: % specific lysis = (1- (ratio of no T cell control mice) / (ratio 
of ACT mice)) x 100, where ratio = % OTII / % TRP). 
 
Western blot 
Nuclear protein from Th17 cells cultured for 7, 14, or 21 days was extracted 
via NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific) then 
subjected to western blot. The following primary antibodies were used: mouse anti-
h/m -catenin clone 14/beta-catenin (BD), rabbit anti-h/mHistone H3 clone D1H2, 




rabbit anti-h/mSTAT3 clone D3Z2G (Cell Signal), rat anti-h/mRORt clone AFKJS-
9, rabbit anti-h/mTCF7 clone EPR2035 (abcam), mouse anti-h/mTbet clone 4B10 




For lung histology and morphometry, lungs were inflated en-bloc and fixed 
with 4% buffered paraformaldehyde at a constant hydrostatic pressure of 25 cm 
and further immersed in fixative for 48 hours. The inflated lungs were embedded 
in paraffin and 4 μm sagittal stepped sections were stained with hematoxylin and 
eosin (H&E) for histological evaluation. In total 10 stepped sections from each lung 
were analyzed to calculate the volume of metastatic tumor in each group using an 
automated motorized stage Olympus BX61 scope to generate lung superimages 
using Visiopharm software. The total area of lung and tumor mets was calculated 




 Library preparation: mRNA libraries were prepared using the TruSeq 
RNA V2 kit(Illumina).  Cleaved RNA fragments were copied into first strand cDNA 




single ‘A’ base addition and ligation to the adapter followed. The product was then 
purified and enriched with PCR to create the final cDNA library. Transcriptome 
sequencing: cDNA libraries were clonally clustered onto the sequencing flow cell 
using the c-BOT (Illumina) Cluster Generation Station and Hiseq Rapid Paired-
End Cluster Kit v2 (Illumina). Clustered flow cells were sequenced on the 




Kaplan-Meier survival curves were assessed for significance using a log 
rank test between treatment groups. A p-value of <0.05 was considered significant. 
Comparisons between two groups were analyzed using a two-tailed student’s t-
tests with Welch’s correction for parametric distribution or Mann-Whitney signed 
rank tests for non-parametric distribution. A p-value of <0.05 was considered 
significant. For comparisons between multiple groups, a one-way repeated 
measures ANOVA was performed. A p-value of <0.05 was considered significant. 
 
Study Approval  
Studies were approved by the IACUC of the Medical University of South 
Carolina (ARC #3039). De-identified human PBMCs were collected under 
approval of our IRB (pro13570). Human T cells were engineered via approval from 




Chapter 3: Enhanced function and prolonged antitumor activity of 




The tumor is a notoriously immunosuppressive environment where tumor-
reactive T cells are thwarted by a variety of inhibitory signals (9-11). 
Lymphodepletion with total body irradiation (TBI) prior to transfer of tumor-
infiltrating or gene-engineered T cells improves treatment outcome in cancer 
patients (132) in part by depleting immunosuppressive host cells. These 
immunosuppressive cells include myeloid-derived suppressor cells (MDSCs), 
regulatory T cells (Tregs) and other cells that compete for homeostatic -chain 
cytokines such as natural killer cells and non-tumor-specific T cells (96, 133, 134). 
Lymphodepletion also enhances the antitumor activity of CD8+ T cells by activating 
innate immune cells via microbial translocation, a process that promotes the 
liberation of gut microbes from the compromised bowel into the blood (84). Recent 
findings revealed that activated dendritic cells (DCs) from lymphodepleted patients 
secrete pro-inflammatory cytokines IL-12 and IL-23, which further improve the 
function of human tumor-infiltrating CD8+ T cells (135). Preclinical work has 
demonstrated that lymphodepletion resets DC homeostasis and increases their 




better T cell priming and antitumor responses (136). While the role of 
lymphodepletion on IL-2-expanded CD8+ T cells (Tc0 − i.e. classic IFN-+CTLs) is 
well studied, how and to what extent lymphodepletion regulates the plasticity, 
memory, and antitumor activity of IL-17A-producing CD8+ T cells (Tc17) remains 
unclear. Given that murine and human IL-17A-producing T cells have shown 
preclinical promise in adoptive cell transfer (ACT) therapies (93, 94, 137), it is 
important to understand how lymphodepletion regulates antitumor Tc17 cells. 
An important benefit of lymphodepletion is the promotion of homeostatic 
cytokine production by the host (81) which in combination with the removal of 
cytokine sinks, creates an environment where T cells can engraft at high numbers 
and persist (74, 138). In a recent study, IL-12 (which is also produced after TBI), 
primed CD8+ T cells to be more responsive to homeostatic cytokines, including IL-
7 (73). This is important as IL-7 is classically known to support naïve and memory 
cells (72). Thus, IL-12 seems to support CD8+ T cell memory. IL-17 producing T 
cells are reported to have active Wnt/-catenin signaling, a characteristic of stem 
memory T cells (Tscm) which exert long-lived protection against tumors (60, 64). 
We hypothesize that IL-17 producing CD8+ T cells (Tc17) would therefore 
synergize with lymphodepletion due to a durable memory phenotype. Thus, we 
propose that Tc17 cells will be able to exert stronger and more durable antitumor 
responses because of their inherent memory properties and improved 




In addition to its effects on memory, we hypothesized TBI would also impact 
Tc17 function through a process called plasticity. Certain CD4+ T helper (Th) 
subsets display considerable functional plasticity; that is, Th17 cells can be 
converted to Th1 cells or Treg cells, under distinct polarizing conditions (139). 
Likewise, Th2 cells can convert into a unique IL-9-secreting subset called Th9 cells 
(140). In contrast, Th1 cells are considered functionally less plastic. As Tc17 cells 
represent a recently described IL-17-producing CD8+ T cell population, the 
capacity and extent of plasticity of this subset and its consequence in tumor 
immunity has yet to be fully appreciated. Several labs have shown that plasticity in 
CD8+ Tc17 cells exists in vivo, as IL-17A-secretors convert to IFN--secreting T 
cells in mice and promote destruction against tumors in lymphodepleted mice (137, 
141-143). Additionally, Th17 cells can convert to Th1 cells and induce diabetes to 
a greater extent in lymphopenic hosts than in non-lymphopenic animals (144). 
Together, these studies suggest that host preconditioning regulates the 
pathogenicity of Tc17 cells. Herein, we investigate how lymphodepletion regulates 
the functional plasticity and antitumor capacity of Tc17 cells in mice with 
established melanoma.  
We show that increasing the intensity of lymphodepletion from a non-
myeloablative (5 Gy) to a myeloablative (9 Gy) TBI preparative regimen (which 
requires hematopoietic stem cell (HSC) support) accentuates the antitumor 
capacity of both Tc0 and Tc17 adoptively transferred T cells, in part by increasing 




accelerated the conversion of Tc17 IL-17A producers into IL-17A/IFN- double 
producers and IFN- single producers. Tc17 cells mediated superior tumor 
regression in myeloablated mice compared to lymphoreplete or non-myeloablated 
mice. Additional investigations revealed that TBI altered the composition of the 
host’s myeloid compartment including enhancing the number of host DCs, 
macrophages and granulocytic MDSC before their eventual disappearance. DCs 
were strongly activated via TBI, as indicated by their elevated expression of 
several co-stimulatory molecules post-irradiation. Escalating the level of irradiation 
also increased IL-12 and IL-23 secretion by irradiated DCs to a greater level than 
macrophages. As cytokines in the IL-12 family differentially regulate the function 
of Tc17 cells in vitro, we sought to determine how these TBI-induced cytokines (IL-
12 versus IL-23) impact the memory, function and antitumor activity of Tc17 cells 
in vivo. Blockade of IL-12 (but not IL-23) reduced the antitumor activity of Tc17 
cells in myeloablated mice. Conversely, Tc17 cells primed with IL-12 in vitro 
enhanced tumor regression in vivo and IL-12 priming increased Tc17 frequencies 
compared to host lymphocytes and enhanced their infiltration into the tumor similar 
to myeloablation. In vitro, Tc17 cells co-expressed RORt and T-bet and co-
secreted IFN- and IL-17A when primed with IL-12. Of clinical significance, 
administration of IL-12 to lymphoreplete (non-irradiated) mice further enhanced the 
antitumor activity of Tc17 cells (in vitro primed with IL-12), leading to long-term 




TBI-induced IL-12 enhances Tc17 memory, plasticity and induces durable 
antitumor activity, a finding that may have a role in the cellular therapy of cancer.  
 
Lymphodepletion augments the antitumor capacity of Tc17 cells more than 
Tc0 cells 
A non-myeloablative preparative regimen consisting of 5 Gy total body irradiation 
(TBI) prior to adoptive cell transfer (ACT) of IFN-+CD8+ T cells (Tc0), vaccination 
with vaccinia virus hgp10025-33 and bolus IL-2 induces regression of established 
B16F10 melanoma in mice (133). Increasing lymphodepletion to a myeloablative 
regimen requiring 9 Gy TBI and stem cell support augments ACT therapy without 
the need for vaccination (145). (Vaccine independence may be a key feature in the 
translation of these findings to humans, as vaccines for transferred T cells are not 
always available.) The mechanisms by which patient preconditioning with TBI 
enhances ACT treatment outcome is multifaceted, consisting of depleting 1) host 
lymphocytes that act as cytokine sinks (homeostatic cytokines are essential for the 
engraftment and expansion of infused T cells), 2) suppressive regulatory T cells 
and 3) myeloid derived suppressor cells (MDSCs) within the tumor while 
concomitantly activating 4) antigen presenting cells (APCs) of the innate immune 
system (84, 146). While lymphodepletion augments the engraftment, function and 
antitumor activity of infused Tc0 cells, it is unclear how and to what extent different 
intensities of host preconditioning impacts the antitumor properties of IL-17A-




that has shown promise in preclinical tumor models (137). We hypothesized that 
increasing the level of host preconditioning would augment the antitumor activity 
of Tc17 cells to a greater extent than Tc0 cells. To test this idea, we pre-
conditioned mice bearing 7 day old B16F10 melanoma tumor with either non-
myeloablative (5 Gy) or myeloablative (9 Gy plus 104 hematopoietic stem cell 
transplantation) lymphodepletion regimens one day before transfer of pmel-1 Tc0 
or Tc17 cells (pmel-1 cells: TCR Tg reactive against the tumor antigen gp100). 
Lymphoreplete mice were used as a control (0 Gy). Mice were not vaccinated with 
hgp10025-33-expressing vaccinia virus, but were treated with bolus high dose IL-2. 
We found that adoptive transfer of pmel-1 CD8+ T cells programmed to a Tc17 
phenotype mediated greater regression of melanoma than pmel-1 Tc0 cells in all 
conditioning regimens (Figure 3-01A-C). Moreover, a myeloablative regimen (9 Gy 
+ HSC) was superior to non-myeloablative preconditioning (5 Gy) in augmenting 
the antitumor activity of transferred pmel-1 Tc17 cells, resulting in curative memory 
responses in myeloablated mice (9 Gy + HSC>5 Gy, Figure 3-01B-C).  
 
Higher doses of TBI increase the numbers of both Tc0 and Tc17 cells in the 
tumor 
 Given that pmel-1 Tc17 cells mediate superior antitumor responses in 
myeloablated mice than Tc0 cells (Figure 3-01C), we hypothesized that Tc17 cells 
traffic to the tumor more efficiently than Tc0 cells. We also posited that donor Tc17 




Figure 3-01. Adoptively transferred Tc17 cells are uniquely enhanced by a 
myeloablative preparative regimen.  
C57BL/6 mice were injected with 3x10
5
 B16F10 melanoma. After 10 days, these 
mice were infused with either ten million Tc17 or Tc0 cells and high dose rhIL-2 
after either (A) no irradiation (0 Gy), (B) non-myeloablative 5 Gy TBI, or (C) 
myeloablative 9 Gy TBI with hematopoietic stem cells (HSC) one day prior to 
transfer. Data are representative of 3 independent experiments (mean ± SEM; 
n=5 mice per group). * = p<0.05, ** = p<0.01, *** = p<0.001, one way repeated 




host CD8, CD4 and NK cells) than donor Tc0 cells in myeloablated mice. To test 
this concept, we evaluated the impact of a nonmyeloablative (5 Gy) versus 
myeloablative (9Gy+HSC) preparative regimen on the engraftment of transferred 
pmel-1 Tc0 or Tc17 cells to the remaining host cells in the tumor of mice. We used 
the congenic marker V13 to distinguish pre-activated donor Pmel-1 Tc0 or Tc17 
cells from the ablated host cells in mice that received TBI. As Wrzesinski et al. 
reported (145, 147), we also found that transferred pmel-1 Tc0 prevailed at a 
higher ratio to remaining host CD8+T, CD4+T and NK cells in the tumor of mice 
receiving myeloablative TBI with HSC transplant (9 Gy + HSC) when compared 
with mice receiving no irradiation (0 Gy) or a nonmyeloablative regimen (5 Gy) 
(Figure 3-02A-C). 
In contrast to our hypothesis, transferred pmel-1 Tc17 cells trafficked to the 
tumor at a comparable ratio against host CD8+ T cells as pmel-1 Tc0 cells (Figure 
3-02A) in all regimens. Interestingly, only in the myeloablative setting (9 Gy + HSC) 
did transferred Tc17 cells reside in the tumor at a slightly higher ratio to host CD4+ 
T and NK cells compared to transferred Tc0 cells (Figure 3-02B-C). Since TBI 
appeared to enhance donor Tc17 cells infiltration into the tumor over host elements 
as effectively as donor Tc0 cells at all three levels of host preconditioning (0, 5 and 
9 Gy + HSC), it remained unclear why escalating TBI doses preferentially 




Figure 3-02. Tumor infiltration by Tc0 and Tc17 cells is enhanced in a dose 
dependent manner by TBI.  
Mice bearing B16F10 melanoma were conditioned with either 0 Gy, 5 Gy, or 9 
Gy (+HSC) TBI, before infusion of 10
6 





) T cells to host (A) CD8+, (B) CD4+ and (C) NK1.1+ NK cells in the 
tumor as assayed by flow cytometry 5 days after transfer. Representative of two 





TBI causes plastic conversion of Tc17 and a higher response to antigen re-
stimulation than Tc0 cells  
To determine whether TBI enhanced the function of the transferred Tc17 
cells more than Tc0 cells in vivo, we measured IL-17A and IFN- secretion by 
infused pmel-1 Tc17 or Tc0 cells before (day -1) and after transfer (day 2 and day 
20) into mice given different TBI preconditioning regimens. Prior to transfer, pmel-
1 Tc0 and Tc17 cells secreted high levels of IFN- and IL-17A, respectively, upon 
hgp10025-33 antigen re-stimulation (Figure 3-03A). Further, as previously reported 
(145, 147), increasing the level of lymphodepletion augmented the function of 
pmel-1 Tc0 cells in vivo, as indicated by their increased capacity to secrete IFN-. 
On day 2 post-transfer, IFN- production by pmel-1 Tc0 cells was highest in mice 
given 9 Gy TBI (72%), followed by mice given 5 Gy TBI (61%) versus those not 
given TBI (54%). Pmel-1 Tc17 cells produced nominal IFN- but ample IL-17A two 
days after infusion into non-irradiated mice. Interestingly, the greatest functional 
plasticity of pmel-1 Tc17 cells was observed in those infused into mice pretreated 
with 9 Gy TBI (+HSC), as these cells dramatically converted from mainly IL-17A 
producers (day -1 before transfer) into those that co-secrete ample IL-17A and IFN-
 (25%) and IFN- alone (31%) two days after infusion (Figure 3-03B). By day 20, 
transferred pmel-1 Tc17 cells produced no IL-17A but high amounts of IFN-. To 
our surprise, by day 20, transferred pmel-1 Tc17 cells produced more IFN- than 
pmel-1 Tc0 cells at any level of lymphodepletion indicating an increased memory 
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Figure 3-03. TBI induces plastic conversion of Tc17 cells to IFN- production.  
IFN- and IL-17 production by pmel-1 Tc17 or Tc0 cells (A) one day before, and 
(B) 2 or (C) 20 days after transfer into mice given increasing levels of TBI. Data 




capacity of the transferred cells to mount a recall response to antigen (Figure 3-
03C). Our data show that increasing the intensity of host preconditioning rapidly 
converts Tc17 cells from IL-17A to IFN- producers in myeloablated mice and Tc17 
cells ultimately secrete more IFN- than Tc0 cells. Both the magnitude and duration 
of this improved Tc17 functionality may account for the pronounced tumor 
destruction observed in myeloablated mice compared with non-irradiated or non-
myeloablated mice. 
 
Lymphodepletion enhances the activation and maturation of DCs 
Because dendritic cells (DCs) are the APCs specialized for triggering T cell 
responses (148), we hypothesized that an increase in the activation of host DCs 
following TBI was responsible for initiating the functional plasticity (Figure 3-03) 
and antitumor activity of pmel-1 Tc17 cells in myeloablated mice (Figure 3-01C). 
To test this idea, we first examined the fate of host DCs and macrophages in the 
spleens of B6 mice following host preconditioning with either a non-myeloablative 
(5 Gy) or myeloablative (9 Gy + HSC) preparative regimens compared to host DCs 
and macrophages in lymphoreplete animals (0 Gy-control). TBI reduced the overall 
cellularity of recipient spleens 12 hours after both a non-myeloablative (5 Gy) or 
myeloablative regimen (9 Gy + HSC), (90.3% and 93.3% respectively) (Figure 3-
04A). However, the frequency of host CD11c+CD11b+ DCs and CD11b+F4/80hi 
macrophages increased substantially in recipient spleens (Figure 3-04B). Further, 




following TBI (Figure 3-04C), and by day 5 >95.0% of host DCs and macrophages 
in the spleen were eliminated in irradiated animals (not shown). Since T cell 
activation is induced by mature DCs in vivo (148), we next sought to determine if 
host DCs might be differentially activated following various levels of 
lymphodepletion but prior to their disappearance. Twelve hours post TBI, host DCs 
from irradiated mice (5 Gy and 9 Gy + HSC) dramatically increased their 
expression of MHC I (H2-Db) and costimulatory ligands CD86, CD80, ICOS ligand 
(ICOSL), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L) and CD70 (Figure 3-04D). 
To our surprise, only OX40L expression was increased in macrophages 12 hours 
after TBI (Figure 3-04D). Collectively, our data suggest that TBI induces the 
activation of host DCs before their rapid elimination, but if TBI regulates the ability 
of pre-terminal DCs to secrete pro-inflammatory cytokines and influence 






Figure 3-04. TBI enhances the frequency and activation status of host DCs.  
(A) total number of splenocytes in mice 12 hours after preconditioning with 0, 5, 









macrophages in spleens of nonirradiated, 5 Gy and 9 Gy irradiated mice. Data 
are representative of three independent experiments (n= 7 mice per group). (C) 








 macrophages in 
spleens of nonirradiated, 5, and 9 Gy irradiated mice. (D) mean fluorescent 
intensity (MFI) of activating ligands on splenic DCs and macrophages. * = 




Lymphodepletion rapidly induces IL-12 family cytokine production by 
dendritic cells 
We next performed kinetic analysis of dendritic cells from non-myeloablated 
and myeloablated mice to determine how long activated DCs remain present and 
functional in the irradiated animal. To monitor function, we measured levels of IL-
12p40 (a subunit shared by both IL-12 and IL-23 (149)) in the serum of irradiated 
mice. Although both 5 and 9 Gy TBI decrease the absolute number of splenic 
CD11c+DCs in mice by day 3 (Figure 3-05A-B, open diamond), a robust and 
transient increase in the absolute number of activated CD11chiMHCII+CD86hi DCs 
was observed in irradiated mice within 6-24 hours post TBI (Figure 3-05A-B, black 
square). Interestingly the peak of CD11chiMHCII+CD86hi DC activation was more 
rapid in mice given a myeloablative (9 Gy + HSC) regimen than in mice given a 
non-myeloablative (5 Gy) regimen (6 hrs versus 24 hours, respectively, see Figure 
3-05A-B). Yet, IL-12p40 was detected within 6-12 hours in the serum of mice given 
either TBI regimen (Figure 3-05C) but was significantly lower in non-irradiated mice 
(0 Gy-basal is <100pg/ml, not shown). Moreover, significantly higher IL-12p40 was 
detected in the serum of mice given a myeloablative preparative regimen than in 
the serum from non-myeolablative mice.  
Based on our finding that IL-12p40 was increased in the serum of irradiated 





Figure 3-05. TBI rapidly activates dendritic cells in the spleen.  
Splenic DCs were isolated from mice given (A) 5 Gy TBI or (B) 9 Gy (+HSC) 
TBI 6, 12, 24, 48 and 72 hours after irradiation, and analyzed for expression of 
CD11b, CD11c, CD86 and MHCII by flow cytometry. (C) IL-12p40 in serum from 
non-myeloablated (5 Gy TBI) or myeloablated mice (9 Gy TBI + HSC) at 12 
hours, 24 hours, and 48 hours following TBI by ELISA. Data representative of 
three separate experiments. (D) Levels of IL-12 and IL-23 produced by dendritic 
cells from spleens of mice receiving escalating doses of irradiation. One day 





from mice given 0, 5, or 9 Gy (+HSC) TBI, and dendritic cells were plated 
overnight in cell media.  After 18 hours, supernatant from cultures was collected 
and analyzed via ELISA. Data are representative of 2 independent experiments 





 Irradiation. As anticipated, DCs isolated from the spleen of myeloablated mice (9 
Gy + HSC) secreted significantly more IL-12 and IL-23 one day following TBI than 
DCs from 5 Gy irradiated and non-irradiated mice (Figure 3-05D). Moreover, the 
amount of IL-12 and IL-23 secreted by DCs was proportionate to increases in TBI. 
Macrophages also secreted IL-12 and IL-23 due to TBI but to a markedly less 
amount than DCs (not shown). Our findings underscore that myeloablation 
augments the function of host DCs, as demonstrated by their heightened secretion 
of IL-12 and IL-23 compared to DCs from non-irradiated or non-myeloablated mice. 
 
Lymphodepletion triggers changes in MDSC subsets in tumor-bearing mice 
Pmel-1 T cells engineered to secrete IL-12 eradicate melanoma when 
infused into mice (150), and one impact of  IL-12 signaling in the tumor 
microenvironment is  a programmatic change in dysfunctional myeloid-derived 
suppressor cells to an inflammatory phenotype which enhances pmel-1 T cell-
mediated tumor regression (151, 152). Specifically, they found that IL-12 
decreased monocytic CD11b+ Ly6ChiLy6Glo cells (MDSC-M) but increased 
granulocytic CD11b+ Ly6Chi Ly6Ghi cells (i.e. MDSC-G) in the tumor (151). Thus, 
as myeloablation (9Gy+HSC) increases IL-12 secretion by host DCs, we 
rationalized that this regimen altered the MDSC-G and MDSC-M cell composition 
in myeloablated mice compared to in non-irradiated mice. Using flow cytometry, 
we examined the presence of these two MDSC subsets in the spleen of 




mice 12 hours after TBI. Indeed, the frequency and absolute number of splenic 
MDSC-G cells was increased in myeloablated mice (9 Gy + HSC) over MDSC-M 
cells compared to in non-irradiated mice or in mice given a non-myeloblative 
regimen (Figure 3-06A-B). Yet, few of these subsets remained in the spleen, blood 
or tumor of recipient mice 5 days post TBI. Moreover, we found that TBI transiently 
induced MDSC-M but not MDSC-G cells to express a plethora of co-stimulatory 
molecules, including CD86, CD70, CD80, 4-1BBL and ICOS ligand (Figure 3-07A-
B). Collectively, our data reveal that TBI alters the balance and activation status of 
DCs, macrophages, MDSC subsets in vivo and hosts DCs from irradiated mice 







Figure 3-06. Granulocytic MDSCs are transiently increased over monocytic 
MDSCs in tumor-bearing mice given TBI.  
(A-B) Mice were conditioned with either no irradiation (0 Gy), non-myeloablative 
5 Gy TBI, or myeloablative 9 Gy TBI with hematopoietic stem cells (HSC). 














(i.e. MDSC-G). Data is representative of three experiments. ** = p<0.01; one way 
repeated measures ANOVA.  
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Figure 3-07. TBI increases activating ligands on MDSC-M but not 
 MDSC-G.  













 MDSC-G (B) in the spleens of mice receiving 0, 5, or 9 
Gy irradiation 1 day prior to spleen harvest; n=3 mice per group; * = p<0.05, ** 




TBI-induced IL-12 augments the antitumor activity of transferred Tc17 cells 
We next sought to determine if TBI-induced IL-12 or IL-23 cytokines were 
responsible for the improved antitumor activity of the transferred pmel-1 Tc17 cells 
in myeloablated mice. To do this, we neutralized IL-12 or IL-23 with IL-12p35 or 
IL-23p19 (subunits distinctly expressed on IL-12 or IL-23, respectively) in mice pre-
conditioned with a myeloablative therapy prior to infusion of pmel-1 Tc17 cells. IL-
12 appeared important for Tc17 cell-mediated tumor immunity in myeloablated 
mice, as melanoma regression was appreciably compromised in mice given 
neutralizing IL-12p35 antibodies compared to treatment groups given an isotype 
control (Figure 3-08). Unexpectedly, despite the role of IL-23 as a key maintenance 
signal for Th17 cell function and expansion (153), neutralizing this cytokine (IL-
23p19) did not impair Tc17 treatment in myeloablated mice nearly as much as IL-
12 depletion did (Figure 3-08). Additionally, IL-12 or IL-23 neutralization did not 
impact treatment outcome in mice that were not infused with Tc17 cells (Figure 3-
08). Our data suggest that TBI-induced IL-12, at least in part, augments Tc17 cell-
mediated tumor regression in myeloablated mice.  
 
IL-12 and IL-23 distinctly regulate the functional plasticity, cytotoxicity and 
transcription factor profile of adoptive transferred tumor-reactive Tc17 cells 
Given that TBI-induced IL-12 augments pmel-1 Tc17 cell antitumor activity 
in myeloablated mice (Figure 3-08), we surmised that if Tc17 cells were in vitro 




Figure 3-08. TBI induced IL-12 enhances the antitumor activity of Tc17 cells in 
myeloablated mice more than IL-23.  
B16F10 tumor bearing mice received 9 Gy TBI (+HSC) were either infused or 
not with pmel-1 Tc17 cells. Mice were injected 0 and 24 hours post-transfer with 
100 μg neutralizing antibodies against either IL-12p35 or IL-23p19 or IgG 





mice would require less lymphodepletion. We also posited that IL-12 would bolster 
the functional plasticity of pmel-1 Tc17 cells in vitro, similar to that seen with pmel-
1 Tc17 cells from myeloablated mice (9 Gy TBI + HSC, Figure 3-03B). As 
expected, IL-12-primed Tc17 cells were highly poly-functional, as 74% secreted 
IL-17A, 52% secreted IFN- and 41% co-secreted IL-17A plus IFN- (Figure 3-
09A). Conversely, IL-23-primed Tc17 cells maintained high IL-17A production 
(66%) and suppressed IFN- (8%) (Figure 3-09A). In contrast to Tc17 cells, neither 
IL-12 nor IL-23 priming enhanced the ability of pmel-1 Tc0 cells to co-secrete IL-
17A and IFN- (Figure 3-09A). These findings signify that IL-12 triggers the 
functional plasticity of Tc17 cells in vitro, as demonstrated by their robust capacity 
to co-secrete IL-17A and IFN-. 
Tc0 cells are more cytotoxic than Tc17 cells in vitro (137). Thus, we next 
sought to determine how IL-12 and IL-23 regulate the cytotoxicity of Tc0 versus 
Tc17 cultures by measuring their release of Granzyme B. We found that priming 
Tc0 cells with IL-12 or IL-23 only marginally increased the population of Granzyme 
B/IFN- double producers (76% unprimed vs. 84% primed) and all Tc0 cultured 
cells secreted high amounts of Granzyme B (Figure 3-09B). Unprimed Tc17 cells 
by contrast expressed low basal levels of Granzyme B (20%), and priming with IL-
12 enhanced Granzyme B secretion (38%) with the majority of these cells also 
producing IFN- (23 of 38%). Conversely, IL-23 did not induce Tc17 cells to 




Figure 3-09.  IL-12 and IL-23 distinctly regulate the function, cytotoxicity and 
transcriptional profile of Tc0 and Tc17 cells.  
Flow analysis of Tc0 and Tc17 cells either unprimed or in vitro primed with IL-12 
or IL-23 5-6 days post activation. (A) IL-17A and IFN-γ secretion by Tc0 and 
Tc17 cells. (B) IFN-γ and granzyme B production by Tc0 and Tc17 cells. (C) 
RORT and T-bet transcription factor expression. Results representative of 5 
independent experiments. (D) Memory phenotype of pmel-1 Tc0 and Tc17 
cultures based on CD44 and CD62L expression as analyzed by flow cytometry. 




09B). Thus, IL-12 increases the cytotoxicity of Tc17 cells, as revealed by their 
marked gain in IFN- and Granzyme B production. 
We next sought to investigate how IL-12 and IL-23 regulates the expression 
of transcription factor RORt and T-bet in pmel-1 Tc17 cells. The transcription 
factor T-bet is important for sustaining IFN- production by CD8+ T cells while 
transcription factor RORγt is well known to promote IL-17A secretion by Tc17 cells 
(154, 155). Using flow cytometry, we found that classic Tc17 cells expressed high 
levels of RORt and nominal T-bet. Yet, IL-12 priming decreased RORt and 
increased T-bet expression in Tc17 cells while IL-23 maintained RORt (Figure 3-
09C). Conversely, Tc0 cells expressed nominal RORt and T-bet. IL-23 did not 
induce RORt expression in Tc0 cells. However, IL-12 but not IL-23 significantly 
increased T-bet expression in Tc0 cells (Figure 3-09C) which is not surprising, 
given that IL-12 has been reported to induce T-bet in T cells (156). In summary, 
IL-12 and IL-23 differentially regulate RORt and T-bet in antitumor Tc17 cells, 
which likely explains why they co-secrete IFN- and IL-17A in myeloablated 
animals (Figure 3-03B).  
 Given that TBI appeared to improve the memory response of Tc17 cells 
based on the durable tumor eradication Tc17 cells induced in myeloablated 
animals, , we wanted to determine if IL-12 promoted a shift in the Tc17 cultures 
from a more differentiated effector (CD62LloCD44hi) memory phenotype to a less 
differentiated central (CD62LhiCD44hi) memory phenotype (61). Tc17 cells 




profile, as previously reported (93, 137). Interestingly, IL-12 only increased the 
frequency of central memory cells in the Tc0 but not Tc17 cell culture (Figure 3-
09D). Collectively, our data reveal that priming Tc17 cells with IL-12 increases their 
functional and transcriptional plasticity in vitro to a more inflammatory and cytotoxic 
phenotype type. Yet, the potentiating effect of TBI on the persistence of Tc17 cells, 
the longevity of their antitumor response, and their recall cytokine production to 
antigen, cannot be explained by IL-12 induced CD62L expression, on Tc17 cells. 
 
L-12 priming augments the antitumor potential of Tc17 cells by enhancing 
trafficking and persistence 
Given that TBI induces host DCs to secrete high IL-12 and IL-23 levels in 
heavily pretreated mice (9 Gy TBI + HSC) (Figure 3-05), we assessed whether 
priming Tc17 cells with IL-12 or IL-23 in vitro would augment their antitumor activity 
in mice preconditioned with a lower intensity and less toxic level of 
lymphodepletion (i.e. 5 Gy TBI). To address this idea, we transferred Tc17 cells 
that were primed with IL-12 or IL-23 in vitro into melanoma tumor-bearing mice 
conditioned with a non-myeloablative (5 Gy TBI) preparative regimen. As an in 
vitro vaccination, pmel-1 subsets were re-stimulated with irradiated splenocytes 
presenting hgp10025-33 peptide prior to transfer into recipient mice (131). Tc17 cells 
primed with IL-12 mediated tumor regression to a greater extent than unprimed or 




Figure 3-10.  Pmel-1 Tc17 cells primed with IL-12 mediate potent antitumor 
responses in vivo.  
Ten million pmel-1 Tc17 cells were primed with either IL-12 or IL-23 in vitro then 
transferred into mice bearing established B16F10 melanomas. Recipient mice 
were irradiated with 5 Gy TBI 12 hours prior to adoptive transfer. No adjuvant 
vaccination and no IL-2 support was administered. (A) Pmel-1 Tc17 cells that 
were not primed with cytokines in the IL-12 family served as a control compared 
to (B) IL-23 primed Tc17 cells, and (C) IL-12 primed Tc17 cells. Data 
representative of 2 independent experiments and n=8 per group; * = p<0.05, ** 




due to differences in the initial impact on tumor size, but rather an improved 
capacity to exert tumor control for a longer period of time. 
 Because IL-12 appeared to increase the duration of tumor control by IL-12 
primed Tc17 cells in non-myeloablated mice, we hypothesized this was due to an 
increase in donor T cell numbers in tumor and spleen similar to the trend seen with 
increasing the intensity of TBI. IL-12 priming augmented trafficking of pmel-1 Tc17 
cells to the tumor over host CD8, CD4 or NK cells in myeloablated mice (Figure 3-
11A). Interestingly, the combination of both host preconditioning with 5 Gy TBI and 
priming Tc17 cells with IL-12 increased tumor infiltration of pmel-1 Tc17 cells over 
host cells to ratios similar or greater than those seen in the tumors of 9 Gy 
preconditioned hosts treated with Tc17 cells (Figure 3-11A). While IL-12 priming 
also increased the engraftment of Tc17 cells in the spleens of 5 Gy preconditioned 
hosts over non-irradiated hosts, donor levels were lower than in myeloablated 
hosts (Figure 3-11B). Thus, while IL-12 priming Tc17 cells in vitro augments their 
capacity to migrate to the tumor and regress melanoma in non-myeloablated mice 
to levels seen in myeloablated mice, it cannot fully replicate the increased T cell 






Figure 3-11. Priming Tc17 cells with IL-12 improves trafficking to the tumor but 
does not increase their engraftment in the spleen.  
Unprimed or IL-12 primed Tc17 cells were infused into mice with B16F10 tumors 
conditioned with either no irradiation (0 Gy), non-myeloablative 5 Gy TBI, or 
myeloablative 9 Gy (+HSC) TBI. (A) Relative infiltration of donor pmel-1 Tc17 
cells to host CD8
+
 T cells, host CD4
+
 T cells, or host NK into tumors combined 





, and NK cells in the spleen by flow analysis on day 5 post 
transfer; n=2-5 mice per group; *** = p<0.001, **** = p<0.0001, one way 





Exogenous IL-12 therapy replaces a myeloablative preparative regimen. 
The robust antitumor response by IL-12 primed Tc17 cells in non-
myeloablated hosts prompted us to question if a low dose of IL-12 to non-irradiated 
animals would entirely replace preconditioning the host with TBI. To answer this  
 question, Tc17 cells primed with IL-12 were transferred into non-irradiated mice 
bearing B16F10 melanoma tumors. Mice were then either treated with or without 
exogenous IL-12 or IL-23 (0.3μg, injected subcutaneously) one and seven days 
post T cell transfer. Administration of exogenous IL-12 bolstered the antitumor 
activity of IL-12-primed Tc17 cells in non-irradiated animals (Figure 3-12A). 
Importantly, this treatment mirrored the antitumor activity of Tc17 cells transferred 
into a myeloablated host (IL-12 primed Tc17 cells plus exo. IL-2 (open diamond) = 
Tc17 cells in 9Gy condition (open circle), Figure 3-12A-B). Interestingly, 
exogenous IL-23 treatment did not augment the antitumor activity of IL-12 primed 
Tc17 cells (Figure 3-12A), despite its known role to promote the generation of 
pathogenic Tc17 cells (157). We also found that exogenous IL-12 augmented the 
antitumor activity of IL-12 primed Tc0 cells (Figure 3-12C) but not to the extent 
achieved by IL-12 primed Tc17 cells (Figure 3-12A). Collectively, our data suggest 
that to achieve curative responses in mice not only requires either myeloablative 
TBI or exogenous administration of IL-12 and IL-12 priming of T cells, but still 
requires the selection of T cells for therapy that are long-lived effectors such as 




Figure 3-12. Exogenous IL-12 mediates durable antitumor immunity in non-
irradiated mice infused with IL-12-primed pmel-1 Tc17 cells. 
(A) Unprimed or IL-12-primed Tc17 cells were adoptively transferred into non-
irradiated tumor bearing mice with or without exogenous IL-12 or IL-23 cytokine 
(0.3 μg/mouse subQ) on day 1 and 7 post-transfer. Mice receiving no treatment, 
or only exogenous IL-12 but no T cells were used as controls. (B) Ten million 
Tc17 cells were transferred into either non-irradiated or myeloablated (9 Gy + 
HSC) tumor-bearing hosts.  Mice receiving only myeloablative TBI with HSC 
were used as controls. (C) Ten million IL-12-primed Tc0 cells were transferred 
into non-irradiated tumor-bearing mice with or without exogenous IL-12 
treatment. Data representative of 2 independent experiments and n=8 mice per 






Host preconditioning with lymphodepletion augments the antitumor activity 
of infused IFN-+CD8+ T cells (Tc0) in mice and in humans with melanoma. Yet, 
the extent to which lymphodepletion impacts the fate of antitumor IL-17A+CD8+ T 
(Tc17) cells – an emerging subset showing great promise in ACT murine models—
remains unknown. To address this, we polarized pmel-1 CD8+ T cells to secrete 
IL-17A or IFN- and infused them into melanoma-bearing mice that were either 1) 
not lymphodepleted (0 Gy TBI) or lymphodepleted with 2) a non-myeloablative (5 
Gy TBI) or 3) myeloablative (9 Gy TBI requiring HSC) preparative regimen. We 
found that Tc17 cells regressed melanoma in myeloablated mice to a greater 
extent than in lymphoreplete or non-myeloablated mice (Figure 3-1A-C). 
Moreover, Tc17 cells but not Tc0 cells mediated curative responses in 
myeloablated mice. Additional investigation revealed that Tc17 cells converted 
from mainly IL-17A producers into IL-17A+IFN-+ double producers 2 days after 
transfer into myeloablated mice and that these cells converted more rapidly in 
myeloablated mice than in lymphoreplete or non-myeloablated mice (Figure 3-03). 
Interestingly, lymphodepletion triggered the innate immune system, as 
demonstrated by an increase in the number of dendritic cells, granulocytic MDSCs, 
and macrophages before their disappearance (Figure 3-04 through 3-07). Among 
these cells, dendritic cells showed significant increases in their co-stimulatory 
ligand expression after irradiation (Figure 3-04) and rapidly secreted the pro-




secreted by TBI-activated host DCs appeared to augment the plasticity and 
antitumor activity of transferred Tc17 cells, as blocking endogenous IL-12 but not 
IL-23 reduced the therapeutic efficacy of Tc17 cells in myeloablated mice (Figure 
3-08). Conversely, priming Tc17 cells in vitro with exogenous IL-12 but not IL-23 
enhanced their functional plasticity and capacity to regress melanoma in vivo 
(Figure 3-09 and 3-10). Administration of low dose IL-12 to non-irradiated mice 
further potentiated the antitumor activity of IL-12-primed Tc17 cells (Figure 3-12), 
leading to long-term antitumor immunity in mice without the requisite for 
lymphodepletion.  
Given that IL-12 and IL-23 enhance immune responses to tumors (152, 158, 
159) and because we found that both IL-12 and IL-23 are induced in myeloablated 
mice (Figure 3-05), we suspected that these cytokines were important for 
enhancing Tc17 cell-mediated tumor immunity in myeloablated mice. As expected, 
blocking IL-12 with an antibody that neutralizes IL-12p35 impaired the antitumor 
activity of Tc17 cells in myeloablated mice. Unexpectedly, blocking IL-23 with anti-
IL-23p19 did not impair treatment outcome in myeloablated mice infused with Tc17 
cells (Figure 3-08). While suggestive that TBI-induced IL-12 but not IL-23 is 
responsible for augmenting Tc17-mediated tumor regression in myeloablated 
mice, we should proceed with caution with this interpretation. While neutralizing 
IL-12p35 with this antibody impaired the antitumor activity of Tc17 cells in 
myeloablated mice, it is worth noting that p35 is also part of the cytokine IL-35 (a 




our studies did not examine IL-35 production in irradiated animals, future studies 
on the role of TBI on IL-35 would be interesting in the context of ACT therapy, 
particularly given that IL-35 has been reported to promote cancer growth (161). 
However, based on our findings, IL-12p35 has a positive therapeutic effect on Tc17 
cells in vivo (Figure 3-08). Indeed, IL-12p35 has also been shown to be critical for 
the secretion of IL-18 in vivo-which can also be key for inducing IFN production 
by T cells (162-164). Thus, in future studies it would be of interest to know whether 
blocking IL-12p35 prevents IL-18 secretion, thereby impairing IFN- production by 
transferred Tc17 cells in myeloblated mice. Thus, while it would be worthwhile to 
further delineate p35 for IL-12, IL-18 and IL-35 in myeloablated mice, the difficulty 
due to overlap with these various cytokines is appreciated. 
IL-12 induces toxic side effects in humans, which has hampered its 
translation into the clinic (165). To circumvent these negative side effects of IL-12 
in vivo, we sought to use IL-12 in pmel-1 Tc17 cultures to enhance their function 
and cytotoxicity in vitro and then wash out IL-12 before infusing these cells into 
mice. Via this approach, we found that priming Tc17 cells with IL-12 enhanced 
their function and cytotoxicity in vitro and in vivo (Figure 3-09A-B) . Tc17 cells 
primed with IL-12 greatly increased their IFN- production (52%) compared to 
those primed with IL-23 (8%) (Figure 3-09A). Moreover, IL-12 primed Tc17 cells 
secreted higher amounts of granzyme B (Figure 3-09B). This increase in classical 
Tc1 effector molecules in Tc17 cells correlated with an induction of T-bet and 




reported to convert Tc17 cells to IL-17A/IFN--double producers through 
epigenetic suppression of cytokine signaling 3 (SOCS3) gene promoters (166, 
167). Thus, future studies that investigate the role of how TBI regulates SOCS3 as 
well as STAT signals in transferred Tc17 cells may shed light on their pronounced 
plasticity and antitumor activity in myeloablated mice. When transferred into mice, 
IL-12 primed Tc17 cells showed greater antitumor efficacy than IL-23 primed and 
unprimed Tc17 cells, which we attribute to the increased poly-functionality seen in 
vitro (Figure 3-09), and enhanced capacity to traffic to the tumor over host 
elements in vivo (Figure 3-11). Collectively, our results indicate that the role TBI 
induced IL-12 plays in enhancing Tc17 cell antitumor efficacy is in augmenting the 
function, cytotoxicity and tumor trafficking ability of these cells in vivo.  
We demonstrated that mice infused with IL-12-primed Tc17 cells that were 
also treated with a low dose of exogenous IL-12 experienced durable antitumor 
responses without the normal need for host preconditioning with lymphodepletion 
(Figure 3-12A). However, these potent therapeutic results cannot be recapitulated 
by either 1) administration of exogenous IL-23 given to mice infused with IL-12-
primed Tc17 cells or by 2) exogenous IL-12 given to mice infused with IL-12-
primed Tc0 cells. Our body of work herein underscores that while IL-12 
conditioning potentiates the antitumor activity of any transferred CD8+ T cells, it is 
a particularly potent strategy in combination with Tc17 cells. It is intriguing that IL-
12 signaling enhanced the potency and durability of the Tc17 antitumor response 




phenotype as seen in Tc0 cells, something that would indicate an improved 
capacity to exert long-term immunity. Yet, both TBI and IL-12 did increase the 
persistence of Tc17 cells in the mice, as well as increase their ability to secrete 
IFN- following antigen re-stimulation, both of which are important indicators of a 
memory T cell. It appears that IL-12’s impact on function and trafficking of the Tc17 
cell complimented intrinsic memory properties of the Tc17 cells that allowed for 
potent long-lived immune responses. The CD4+ counterpart of Tc17 cells (Th17 
cells) are reported as having a stem memory phenotype and can exert this type of 
durable antitumor response (85, 88). Future studies will further elucidate the true 
memory capacity of these cells and what mechanisms drive this phenotype in 
these cells.  
In conclusion, it is worth considering the impact of TBI on models of 
lymphodepletion, as many investigators use TBI to study lymphocyte engraftment 
and immunity to foreign, self and tumor tissue (72, 168). Yet, the induction of 
homeostatic expansion of the T cell compartment after TBI preconditioning cannot 
be viewed as simply expanding to fill empty space as was previously thought (74). 
We and others have reported that TBI induces a complex set of events, such as 
microbial translocation (84), which beyond inducing homeostatic cytokine 
production also increases inflammatory signaling including secretion of IL-12 and 
IL-23 from activated DCs. We show that the multiple factors induced by TBI create 
an exclusive environment primed to enhance the efficacy of adoptively transferred 




Chapter 4: Th17 cells are effector cells with durable memory capable of 




Adoptive T cell therapy (ACT) achieves remarkable outcomes for patients 
with objective responses of 54% and complete remissions of 24% (27, 169, 170). 
To accomplish durable results in patients, ACT requires the infusion of large 
numbers of tumor-reactive T cells (~1010 cells) (23-25, 33, 71, 171, 172). Most 
protocols for generating vast T cell numbers require their expansion for up to three 
months with at least one CD3-dependent re-activation (33, 71, 172). Yet, ex vivo 
expansion works in direct opposition to maintaining antitumor efficacy because the 
cytotoxic CD8+ T cells used in clinical trials lose their potency when extensively 
expanded ex vivo. This loss of antitumor efficacy is due to a reduced capacity to 
persist in vivo once CD8+ T cells reach terminal differentiation (46). Additionally, 
this effect occurs rapidly, as even highly potent IL-12-primed CD8+ T cells lose 
antitumor efficacy in as little as one week of expansion (173). Rapid-expansion 
protocols also compromise the integrity of human tumor infiltrating lymphocytes 
(TILs), while TILs that undergo shorter expansion ex vivo persist longer (49, 53-
55).  
Although investigators have developed strategies to prevent T cell 




dilemma using a T cell subset relatively refractory to in vitro expansion induced 
senescence. In murine models of melanoma, TRP-1 Th17 cells (CD4+ T cells 
which express the transcription factor RORt and secrete IL17), offer an alternative 
to melanoma-reactive pmel-1 CD8+ T cells as they mediate a potent response 
against aggressive melanoma in mice even without antigen vaccination and in vivo 
IL-2 support required in pmel-1 CD8+ ACT models (93-95). This remarkable Th17 
antitumor response occurs in part by enhancing CD8+ T cell responses against 
transformed cells (97, 174-176) and via their ability to directly lyse tumor (177, 
178). In both cases, Th17 cells exert superior antitumor immunity compared to Th1 
and other CD4+ T cell subsets (93), as well as superior enhancement of CD8+ T 
cells (97). Also, since Th17 cells show durable effectiveness in vivo and have stem 
memory properties (85, 88), we posited that unlike CD8+ T cells, Th17 cells would 
retain their antitumor capacity even after long-term ex vivo expansion to clinically 
relevant doses. 
We found that even without a rapid expansion protocol (REP), Th17 cells 
were capable of robust growth for 21 days ex vivo yielding ~5,000 times the initial 
CD4+ T cell numbers. Additionally, while exhibiting a CD44hiCD62Llo effector 
memory phenotype, Th17 cells expressed nuclear Tcf7 throughout in vitro culture 
indicating active and preserved stem memory signaling. Unlike Th1 or CD8+ T 
cells, Th17 cells retained their ability to eliminate melanoma tumors over two 
weeks of expansion. Th17 cells were resistant to senescence indicated by 




expression of KLRG1 and TIM3. In contrast, Th1 cells expressed exhaustion 
markers and higher levels of checkpoint receptors and were far more apoptotic 
than Th17 cultures at any time point of expansion. Importantly, Th17 cells 
expanded for either a 7- or 21-day duration ex vivo were equally able to persist in 
the tumor-bearing host after transfer. Despite similar antitumor potency between 7 
and 21 day Th17 cells on a per cell basis, we hypothesized that mediating curative 
responses in mice with large, nearly terminal, tumors would require the full yield of 
Th17 cells generated from three weeks of culture. We found that treatment with 
two or three week expanded Th17 cells rapidly and completely eradicated 
aggressively growing tumors, while the full yield of one week expanded Th17 cells 
was insufficient to control these tumors. Of clinical significance, human Th17-
polarized CD4+ cells also exhibit marked durability in antitumor potency compared 
with Th1-polarized cells when expanded for either 7 or 12 days. Our analysis of all 
parameters of Th17 cell ex vivo preparation for ACT (in vitro time of expansion, 
cell yield, T cell subset, and size of tumor) indicate tumor-reactive Th17 cells 
represent a cell product that can be reliably applied to treat highly aggressive solid 
tumors.  
ACT with Th17 cells still requires transferring large numbers of T cells to 
clear tumors  
The effectiveness of ACT is thought to depend on the transfer of large 
numbers of tumor-specific T cells (46). Yet, because Th17 cells mediate potent 




hypothesized that we could titrate down the number of Th17 cells infused into mice 
without impairing tumor clearance. To test this idea, TRP-1 transgenic CD4+ T cells 
with a TCR specific for tyrosinase related protein-1 (TRP-1, a shared 
melanocyte/melanoma antigen) were polarized to a Th17 phenotype and 
expanded ex vivo for one week. This protocol generated cells with expression of 
the Th17 transcription factor RORt, high IL-17 production, and nominal Tbet (the 
Th1 transcription factor) and IFN (Figure 4-01A-B). We infused decreasing doses 
of Th17 cells (4.5, 1.5 or 0.5e6 cells/mouse) into C57BL/6J mice with established 
B16F10 melanoma preconditioned with non-myeloablative (5 Gy) total body 
irradiation (TBI) (Figure 4-01C). While the highest number of Th17 cells (4.5e6) 
eliminated tumor in most mice, tumor responses and overall survival declined in 
mice treated with fewer Th17 cells (Figure 4-01C-D). Thus, despite their enhanced 
antitumor efficacy and a stem memory profile, Th17 cells require a sufficient 







Figure 4-01. High numbers of transferred Th17 cells are required for successful 
antitumor response. 
(A) Rort and Tbet expression by Th17 cells after 7 days of culture; 
representative of 3 independent experiments. (B) IL-17A and IFN expression 
by Th17 cells after 7 days of culture; representative of 5 independent 
experiments. (C) Th17 cells cultured ex vivo for 9 days were administered to 
mice with B16F10 melanoma after non-myeloablative (5 Gy) total body 
irradiation (TBI) one day prior to treatment with the indicated Th17 cell doses; 
n=6-7 mice/group, representative of 3 independent experiments. (D) Percent 
survival of mice treated with 4.5, 1.5 or 0.5e
6
 Th17 cells/mouse. Kaplan Meier 




REP decreases the antitumor capacity and recall responses of Th17 cells 
Since large numbers of Th17 cells are required to eradicate tumors, we 
tested whether extending in vitro culture time for another week using a rapid 
expansion protocol (REP) with TCR re-activation would improve their yield. To test 
this, as presented in Figure 4-02A, Th17 cells were expanded for two weeks with 
the REP culture undergoing TCR re-activation using TRP-peptide pulsed feeder 
cells at one week. Interestingly, Th17 cells only activated once (primary expansion) 
could effectively expand for two weeks to similar yields as REP Th17 cells (Figure 
4-02B). By day 14, both Th17 and REP Th17 cells were mainly CD44hiCD62Llo 
effector memory (Figure 2C). However, REP Th17 cells were slightly compromised 
in their ability to regress tumors and promote survival in mice (Figure 4-02D-E).  
The decreased antitumor efficacy of REP Th17 cells was not due to 
increased levels of apoptosis, KLRG1, PD1 or TIM3 compared to Th17 cells 
(Figure 4-03A-C). Yet, while the frequency of donor Th17 cells in the spleen and 
tumors of surviving mice was similar to the frequency of REP Th17 cells 40 days 
post-treatment (Figure 4-03D-E), memory recall against TRP-1 antigen by mice 
treated with REP donor Th17 cells was significantly impaired compared to mice 
treated with Th17 cells in an in vivo cytotoxic assay (Figure 4-03F). Thus, rapid 
expansion protocols appear to compromise the antitumor efficacy and antigen 






Figure 4-02. REP does not improve Th17 yield and reduces antitumor efficacy.  
(A) Schematic for growth of Th17 and REP Th17 cultures. (B) Yield of Th17 and 
REP Th17 cells after two weeks of culture, representative of 3 independent 
cultures. (C) CD44 and CD62L memory marker expression on Th17 or REP 
Th17 cells on day 15, n=3 independent cultures. (D) Mice with B16F10 were 
treated with 2e
6
 Th17 cells or REP Th17 cells after 5 Gy TBI; n=10 mice/group, 
representative of 2 independent experiments. (E) Percent Survival of cohorts 
treated with Th17 or REP Th17 cells; Kaplan Meier curves compared by log rank 




Figure 4-03. REP protocol does not induce senescence or apoptosis in Th17 cells 
but does impair antigen recall responses.  
 (A) Propidium iodide (PI) and Annexin V staining on two week expanded Th17 
and REP Th17 cells with or without 12 hour incubation with anti-CD3 antibody; 
n=3 cultures.      (B) KLRG1 and PD1 expression on Th17 and REP Th17 cells 
after two weeks; n=3 cultures. (C) KLRG1 and TIM3 expression on Th17 and 
REP Th17 cells after two weeks; n=3 cultures. (D) Mean frequency ( SEM) of 
donor Th17 or REP Th17 cells in spleen of treated mice; n=5-8 mice/group.  (E) 
Mean frequency ( SEM) of donor Th17 or REP Th17 cells in tumor of treated 
mice with mean; n=5 mice/group. (F) Memory response of donor Th17 or REP 
Th17 cells evaluated by an in vivo cytotoxicity assay reported as mean percent 
specific lysis ( SEM); n=5-8 mice/group. Mean frequency and percent specific 




Th17 cells become less activated but not terminally differentiated during ex 
vivo expansion  
We next sought to determine how long Th17 cells could be expanded in 
vitro without losing antitumor efficacy. We found that Th17 cells could expand for 
three weeks without TCR re-activation (Figure 4-04A). While tyrosinase-specific 
(V14+) CD4+ T cells have a naïve phenotype (CD44loCD62Lhi) when isolated from 
the spleens of TRP-1 mice, Th17 cells exhibited an effector memory phenotype 
with high CD44 and low CD62L expression as early as one week after activation, 
which prevailed throughout culture (Figure 4-04B). This phenotype corroborates 
previous studies with human and murine Th17 cells which found Th17 cells exerted 
long-lived immunity despite an effector memory phenotype (88, 93).  
Because we were not using a REP protocol to expand the Th17 cells, we 
expected that the cells would gradually become quiescent and down-regulate 
activation markers as they were expanded for 21 days in vitro. As expected, 
activation markers CD69 and CD25 (IL-2R) were initially high one week after 
stimulation but progressively declined (Figure 4-04C). Similarly, Th17 cells initially 
expressed high levels of ICOS, which is an important co-stimulatory molecule that 
supports their function and maintenance (94, 179), while the co-stimulatory 
receptor 4-1BB was only increased moderately above pre-activation levels one 
week after activation. In contrast, CD127 (IL-7R) was maintained on Th17 cells 




Figure 4-04. Th17 cells expanded for three weeks enter quiescence while 
maintaining or upregulating memory markers.  
(A) Growth of Th17 cells in culture; n=7 independent cultures. (B) CD44 and 




 T cells before polarization 
and Th17 cells at different time-points in culture via flow cytometry; 
representative of 3-5 cultures (C) Mean MFI ( SEM) of cytokine and co-
stimulatory receptors during ex vivo culture of Th17 cells assessed by flow 




this not only suggests a persistent responsiveness to IL-7 (73), but also a 
persistent memory phenotype. The costimulatory ligand CD28 was similarly 
retained through culture, while CD27, which is associated with adaptive memory 
responses (180), increased between week 1 and week 3 (Figure 4-04C). 
Importantly, the retention of CD127 and CD28, and the increased expression of 
CD27 during expansion, may indicate that Th17 cells are resistant to the 
senescence that naturally occurs in other T cells subsets (181).  
 
Long-term expanded Th17 cells retain antitumor potency 
We next tested whether the pattern of chemokine and co-stimulatory 
receptor expression we observed throughout culture truly indicated a preserved 
memory phenotype and antitumor capacity. We posited that Th17 cells (in contrast 
to CD8+ T cells (46)) would retain antitumor activity as they expanded long-term in 
vitro. To compare Th17 cell antitumor efficacy over ex vivo culture time on a per 
cell basis, Th17 cells were expanded for three weeks with a portion of cells 
cryopreserved at either 1) early (day 6-7), 2) intermediate (day 12-14), or 3) late 
(day 18-21) time points in culture. Th17 cells were then transferred at equal 
numbers (2e6 Th17 cells/mouse) from each time-point into lymphodepleted mice 
bearing established melanoma. Note that for late Th17 culture, the infusion product 
represented a mere 1/2500th of their total cell count. Yet, no matter the duration of 
in vitro expansion, Th17 cells killed tumors (Figure 4-05A) and supported long-





Figure 4-05. Th17 cells expanded for three weeks retain capacity to eliminate 
tumors.  
(A) Mice with B16F10 tumors were treated with equal numbers (2e
6
 
cells/mouse) of Th17 cells from the early, intermediate and late time-points of 
ex vivo culture following 5 Gy TBI one day prior; n=8-9 mice/group, 
representative of 4 independent experiments. (B) Percent survival of mice 
treated in panel A; n=8/9 mice/group, Kaplan Meier curves compared by log 




Th17 cells persist in the host and preserve telomere length and wnt/-
catenin signaling regardless of in vitro expansion time 
T cell persistence correlates with enhanced treatment outcome in 
melanoma patients given ACT (53). Thus, the similar antitumor efficacy mediated 
by early or late culture Th17 cells in mice suggested that these cells – regardless 
of time in vitro – would engraft and persist in mice at similar levels. To test this 
idea, we followed donor TRP-1 CD45.2+ Th17 cells expanded for 7 (early) or 21 
days (late) in CD45.1+ recipient mice over 28 days. Early and late Th17 cells were 
present at equivalent numbers post-treatment at 7, 14, and 28 days in the spleen 
and after 7 days in the tumor (Figure 4-06A). The eye is a common off-site target 
for T cell models specific for melanocyte-associated antigens (i.e. tyrosinase) 
because of melanocytes in the pigment epithelium (182). Here, too, we detected 
early and late Th17 cells at comparable amounts in melanoma-bearing mice 
(Figure 4-06A).  
In ACT clinical trials, a donor T cells with longer telomeres persist better in 
melanoma patients and is associated with improved survival (54, 55). We 
hypothesized that preserved telomere length during expansion both in vitro and in 
vivo might be a mechanism by which Th17 cells, at any stage of expansion, 
preserved their antitumor efficacy after in vitro expansion. Telomere length only 






Figure 4-06. Th17 cells possess the memory cell characteristics of persistence, 
telomere preservation and maintained Tcf7 expression.      
(A) Mean number ( SEM) of donor Th17 cells from early or late culture time-
points in host C57BL/6 spleen, tumor and eye at indicated days post-treatment; 
n=4-5 mice, representative of 2 independent experiments.  Mean cell numbers 
of early or late Th17 cells compared by student’s t-test; ns= not statistically 
significant. (B) hybridized telomere PNA in Th17 cells at early and late culture 
time-points; n=3 independent cultures. (C) Mean MFI ( SEM) of telomere 
length in donor Th17 cells 4 weeks post-treatment; n=5 mice/group. Mean 
telomere MFI compared by student’s t-test; ns = not statistically significant. (D) 
Western blot analysis of nuclear protein from 7, 14, and 21 day expanded Th17 
cells, T= Tcf7, H= Histone H3; representative of 4 independent cultures. (E) 
Quantified Tcf7 protein relative to Histone H3 (Mean  SEM), RR (OD) = relative 
ratio of optical density; n=4 independent cultures; one way repeated measures 




Th17 cells from early and late cultures maintained comparable telomere length 
four weeks post ACT (Figure 4-06C).  
Despite their persistent CD44hiCD62Llo effector memory phenotype, we 
hypothesized that because of their persistence, long-lived immune responses 
against tumor, and preserved telomeres, Th17 cells must have stem cell like 
memory similar to stem memory T (Tscm) cells (60, 64). Indeed, Th17 cells 
expressed Tcf7, a downstream product of active -catenin signaling throughout 
culture (Figure 4-06D-E); the same stemness signaling described in Tscm cells 
(60), and also implicated in memory T cell self-renewal and persistence (183). 
Thus, a partial explanation for the durable antitumor response of Th17 cells may 
be their maintenance of telomere length in vitro and in vivo, as well as continued 
wnt/-catenin signaling.  
 
Th17 cells undergo polyfunctional conversion during expansion but do not 
change their interaction with host immune cells 
We noticed that even without inflammatory signaling such as IL-12, which 
drives Th17 cell conversion to a Th1-like phenotype (termed Th17 plasticity (166, 
184, 185)), Th17 cells became progressively poly-functional. As seen by ELISA 
performed 18 hours after peptide-dependent re-activation, IL-17A and IL-17F 
decreased in concert throughout culture, IL-22 was lost rapidly after one week, and 





Figure 4-07. Th17 cells undergo polyfunctional conversion in vitro but preserve 
Th17 transcription factors.  
(A) Cytokine production by Th17 cells from each time-point in culture analyzed 
via ELISA 18 hours after TRP peptide stimulation (mean  SEM); n=5. (B) 
Western blot of nuclear protein extracts from 7, 14, and 21 day expanded Th17 
cells, R=RORt, S3= Stat3, S1= Stat1, H = Histone H3; representative of 4 
independent cultures. (C) Quantified protein levels relative to Histone H3, RR 





correlated with reduced levels of nuclear Rort and STAT3, although both 
molecules persisted throughout culture (Figure 4-07B-C). Additionally, Th17 cells 
maintained nuclear STAT1, while Tbet was not detected (Figure 4-07B-C).  
We suspected that the increased polyfunctionality of 3 week expanded 
Th17 cells compared to 1 week old counterparts would increase the recruitment of 
host CD8+ cells. In contrast, we found that mice treated with 21 day expanded 
Th17 cells surprisingly had slightly fewer (though not statistically significant) host 
CD8+ cells in the spleen and eyes of recipient CD45.1+mice, indicated by their 
higher ratio of donor Th17 to host cells (Figure 4-08A-B). 
These differences between early and late Th17 cells, as well as previous 
data showing Th17 cells enhance tumor specific CD8+ T cell immunity (97) led us 
to question if early or late Th17 cells utilize endogenous CD8+ T cells to a different 
degree in their antitumor response. We transferred early or late Th17 cells and 
antibody depleted CD8+ T cells to address this question. Interestingly, all groups 
had similar antitumor responses and survival rates (Figure 4-08C-D) suggesting 
that Th17 cells are capable of tumor lysis independent of CD8+ T cells. However, 
one should be conservative with this conclusion as other reports suggest depleting 
host T cells might be beneficial to ACT therapy by removing competition for 
homeostatic cytokines (82) which may have confounded the results. Thus, while 




and interact with host CD8+ T cells in tumor-bearing mice comparably to infused 






Figure 4-08. Polyfunctional conversion of Th17 cells in vitro does not change 
interaction with host CD8
+
 cells between early and late Th17 cells.  
Ratio of donor Th17 cells to host CD8
+
 T cells in (A) spleens and (B) eyes of 
treated mice (mean  SEM); n=5 mice/group. (C) Mice with B16F10 tumors 
were treated with 6e
5
 cells/mouse of early or late Th17 cells after 5 Gy TBI one 
day prior. Starting the week of transfer mice received weekly CD8 depleting 
antibody or isotype control antibody; n=10 mice/group. (D) Percent survival of 
mice treated in panel C; n=10 mice/group, Kaplan Meier curves compared by 




 Th17 cells but not Th1 cells resist senescence and apoptosis in vitro  
We next tested whether TRP-1 Th1 cells, like TRP-1 Th17 cells, could retain 
their antitumor efficacy after long-term ex vivo expansion. While Th17 cells cleared 
tumors similarly after one or two weeks of expansion, two-week expanded Th1 
cells lost their ability to control tumor growth (Figure 4-09A-B). This is similar to the 
loss of antitumor efficacy by CD8+ T cells which we found occurs in IL-12-primed 
pmel-1 CD8+ T cells even without REP. Expanding these cells for only 10 days still 
caused a dramatic reduction in antitumor activity compared to 4 day expanded 
CD8+ T cells (Figure 4-10A-B). Note that the CD8+ T cells lost control of tumor 
even after in vitro activation (a substitute for antigen vaccination (131)) and post-
transfer injections of high dose IL-2, which were not used in either our Th17 or Th1 
therapies.  
To understand why Th17 and not Th1 cells had durable antitumor efficacy 
during expansion, we surveyed expression of memory and other surface markers 
as well as levels of apoptosis in culture overtime. Th1 cells had a significant cohort 
of central memory cells at one week of culture compared to Th17 cells, indicated 
by their CD62L expression (32% on Th1 vs. 4% on Th17). However, by the second 
week, CD62L decreased on Th1 cells by half (Figure 4-11A). Thus, CD62L 
expression on Th1 cells appears to correlate with their antitumor potential similar 
to CD8+ T cells. 
Unlike Th17 cells, Th1 cells maintained CD69 and CD25 expression 
between day 7 and day 14. Yet, importantly, levels of CD25 on early Th1 cells were  
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Figure 4-09. Th1 cells do not retain antitumor efficacy as they expand.  
(A) Tumor burden of mice treated with one or two week expanded Th17 or Th1 
cells compared to no treatment; n=10-16 mice/group, combined from 2 
independent experiments. (B) Percent survival of mice treated with one or two 
week expanded Th17 or Th1 cells compared to no treatment; n=10-16 
mice/group, combined from 2 independent experiments; Kaplan Meier curves 
compared by log rank test; ns = not statistically significant, * = p<0.05.  
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Figure 4-10. CD8
+
 T cells rapidly lose antitumor efficacy even without REP. 
 (A) Mice with B16F10 melanoma were irradiated with 5 Gy TBI then treated the 
following day with 2e
6
 IL-12-primed pmel-1 CD8
+
 T cells cultured for 4 or 10 
days; n=12-15 mice/group; representative of 3 independent experiments. (B) 
Percent Survival of mice treated with IL-12-primed CD8
+
 T cells from 4 days in 
culture or 10 days compared to no treatment mice. Kaplan Meier curves 




Figure 4-11. Th17 cells are resistant to senescence during ex vivo expansion 
compared to Th1 cells.  
(A) CD44 and CD62L on Th17 and Th1 cells expanded for one or two weeks in 
vitro, n=3 independent cultures. (B-C) Mean MFI ( SEM) of extracellular 
receptors during ex vivo culture of Th17 and Th1 cells assessed by flow 




lower than on early Th17 cells indicating a reduced capacity to respond to the 
homeostatic cytokine IL-2. Similarly, Th1 cells also had less CD127 than Th17 cells 
(Figure 4-11B). We assayed the levels of other markers that along with 
homeostatic cytokine receptor levels, can indicate T cell fitness (181, 186). We 
observed that levels of CD28 were lower on early Th1 cells compared to early 
Th17 cells, and CD27 expression decreased on Th1 cells between day 7 and day 
14 in contrast to Th17 cells (Figure 4-11C). Additionally, KLRG1 and the 
checkpoint inhibitor TIM3 were higher at each timepoint on Th1 cells versus Th17 
cells. Interestingly, PD1 expression on early Th17 and Th1 cells was similar, but 
expression of this inhibitory molecule declined by day 14 on Th17 cells while it 
increased on Th1 cells (Figure 4-11C). 
An important difference between Th1 and Th17 cells is their tendency to 
undergo apoptosis and necrosis in culture. At day 7 ex vivo, 18% of Th1 cells were 
single positive for Annexin V (indicating early entry into apoptosis), while 42% 
stained positive for propidium iodide (PI) (indicating either the end stages of 
apoptosis or necrosis). On the other hand, only 2% of Th17 cells were Annexin V 
single positive or PI positive (Figure 4-12A). By day 14, 18% of Th1 cells were 
Annexin V single positive and 3% were PI positive, while Th17 cells had 4% 
Annexin V single positive and no PI positive cells (Figure 4-12A). However, Th1 
cells demonstrated much more sensitivity to activation induced cell death than 
Th17 cells. Twelve hours after TCR engagement with an anti-CD3 antibody we 
observed up to 55% of Th1 cells were Annexin V single positive and 8% PI positive.  
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Figure 4-12. Th1 cells are more sensitive to apoptotic stress and express higher 
levels of senescence markers than Th17 cells regardless of activation status.  
(A) Propidium Iodide (PI) and Annexin V staining on one or two week expanded 
Th17 and Th1 cells. Day 14 Th17 and Th1 cells were either incubated with 
1g/mL anti-CD3 for 12 hours or left as an untreated control; n=3 independent 
cultures. (B) Percent Annexin V single positive Th17 or Th1 cells (graphed with 
mean  SEM) at two weeks expansion with or without reactivation. Reactivated 
Th17 and Th1 cells were incubated with 10 Gy irradiated B6 splenocytes with 
1M TRP-1 peptide for 18 hours; n=4 independent cultures. (C) Mean MFI ( 
SEM) of extracellular receptors during ex vivo culture of Th17 and Th1 cells 




Yet, Th17 cells remained resistant to apoptosis upon reactivation, demonstrated 
by only slight increase in Annexin V staining from 4% to 8% on these cells (Figure 
4-12A). We observed a similar pattern of increased annexin V+ cells in Th1 cells 
but not Th17 cells after TRP-1 and irradiated splenocyte activation (Figure 4-12B).  
To determine if expression of exhaustion/checkpoint molecules was merely 
an artifact of activation, we activated day 14 Th17 and Th1 cells using irradiated 
splenocytes bearing TRP-1 peptide. While CD69 expression increased 
significantly on Th17 cells, KLRG1 did not, and TIM3 and PD1 only increased 
marginally. However, expression of all these markers was higher on Th1 cells 
compared to Th17 cells with or without activation and was not affected by 
activation status (Figure 4-12C). Collectively, or data indicate that Th17 cells 
maintain durable memory responses after long-term expansion in part, because of 
their resistance to senescence and apoptosis, which may explain their improved 
ability to regress tumors compared to Th1 or CD8+ T cells. 
 
Large numbers of Th17 cells cure mice with aggressive tumors  
Up to this point, we tested the antitumor capacity of Th17 cells expanded 
for 1 to 3 weeks on a per cell basis. This ignored the vast expansion of these cells 
by the end of 3 weeks of ex vivo expansion. We hypothesized that more Th17 cells 
(>1e7 million) would be required to ablate large tumors and therefore would 




Th17 cells, which still had remarkably preserved effector potency, to regress large, 
recalcitrant melanoma. To obtain differentially ‘aged’ Th17 cell products and test 
their potential against large tumors, parallel cultures were grown from one Th17 
polarization to early (day 7), intermediate (day 14) or late (day 18) time-points, 
cryopreserved, and then split evenly among 12 mice/group. This protocol yielded 
mean treatment doses of 1.3e6, 9.9e6 or 1.3e7 cells/mouse, respectively to treat 
mice with large melanomas (~136 mm2) (Figure 4-13A). As anticipated, we found 
that tumors regressed rapidly in mice treated with the high numbers of Th17 cells 
from either the intermediate or late cultures (Figure 4-13B). This was evidenced by 
the tumors in these mice reaching peak size earlier and having a smaller peak 
tumor size than mice treated with early Th17 cells (Figure 4-13C-D). Conversely, 
mice treated with 1.3e6 early Th17 cells were unable to control tumor growth with 
most mice succumbing to disease (Figure 4-13B&E).  
 
Infusing more Th17 cells from long-term expansion sets up long-lasting 
memory and protection against multiple re-challenges. 
A common correlate in successful adoptive immunotherapy for melanoma 
is induction of autoimmune vitiligo after treatment (187). Thus, the reduced 
antitumor efficacy of early Th17 cells was paralleled by a delay in onset of 
autoimmune vitiligo (Figure 4-14A) indicating a weaker initial immune response. 
However, all mice given Th17 cells (at any amount or at any age) eventually 




   
Figure 4-13. Successful Th17 cell ACT against large tumors requires the cell 
numbers achieved by long-term ex vivo expansion. 
 (A) Mean ( SEM) number of Th17 cells administered to mice with large 
(median 136 mm
2
) B16F10 tumors from parallel cultures expanded to either 
early, intermediate, or late culture time-points and divided among 12 




 quartiles, bars = min and max values; n=2 
cultures. (B) Tumor control in mice treated with early, intermediate or late culture 
Th17 cells; n=12 mice/group, representative of 3 independent experiments. (C) 
Mean time ( SEM) in days post-treatment until tumors reached peak size 
(mm
2
); n=12 mice/group. One way repeated measures ANOVA; *** = p<0.001. 
(D) Mean ( SEM) peak tumor area (mm
2
) in each mouse before onset of tumor 
control; n=12 mice/group. One way repeated measure ANOVA; * = p<0.5. (E) 
Percent survival of mice treated with early, intermediate or late culture Th17 
cells; n=12 mice/group, representative of 3 independent experiments. Kaplan 





Figure 4-14. Infusing large numbers of Th17 cells after two or three weeks of 
expansion sets up long-term donor residence with enhanced memory response 
against antigen and tumor re-challenge. 
 (A) Onset of vitiligo in treated mice for each group; n=12 mice/group. Kaplan 
Meier curve compared by log rank test; ns = not statistically significant, ** = 
p<0.01.        (B) Clinical scores of vitiligo in mice from early, intermediate, and 
late Th17 cell treatment group after tumor resolution (mean  SEM); n=12 
mice/group. One way repeated measures ANOVA; ns = not statistically 
significant. (C-D) Mean frequency ( SEM) of donor Th17 cells in (C) spleens 
and (D) draining lymph node (dLN) of surviving mice 40 days post-treatment; 
n=5 mice/group. One way repeated measures ANOVA; * = p<0.05, ** = p<0.01. 
(E) Memory recall assessed by in vivo lysis of peptide-pulsed splenocytes 40 
days post-treatment compared to control mice (mean percent specific lysis  




slower onset of vitiligo (Figure 4-14A) a slower halt of tumor growth (Figure 4-13C-
D) and subsequent loss of tumor control (Figure 4-13B) by early Th17 cells 
compared to intermediate and late Th17 cells indicates that a strong and rapid 
immune response, which is ensured by high numbers of infused effector T cells, is 
crucial to a successful therapy.  
We suspected that transferring more T cells would correlate with higher 
numbers of memory T cells. As expected, higher frequencies of donor Th17 cells 
were detected in the spleen and tumor draining lymph nodes (dLN) of mice infused 
with more Th17 cells (intermediate and late cultures) (Figure 4-14C-D). This 
correlated with stronger antigen recall responses, as mice treated with 
intermediate and late Th17 cells had significantly higher rates of TRP-1 antigen-
pulsed cell lysis than early Th17 cell treated mice (Figure 4-14E).  
Since the tumor control and antigen recall responses between intermediate 
and late Th17 cell treated mice were similar, we further tested if treatment with 
intermediate or late Th17 cells yielded the same antitumor immunity by 
administering a second dose of subcutaneous B16F10 to the cured animals. 
However, all animals from both treatment groups were protected from re-challenge 
(Figure 4-15A), underscoring the therapeutic ability of Th17 cells to mediate 
durable tumor immunity. To further test the potency of this therapy, we re-
challenged the mice again with a more aggressive metastatic model. B16F10 
tumor cells were administered intravenously to mice to induce lung 





Figure 4-15. Long-term expanded Th17 cells exert memory responses against 
multiple B16F10 re-challenges.  
(A) Average tumor burden of treatment groups after subcutaneous re-challenge 
with 0.4e
6
 B16F10 compared to no treatment (mean  SEM); n=2-6 mice/group. 
(B) Macroscopic images of lungs and high power microscopic images of 
representative en-bloc sections from intermediate or late Th17 treated mice 
compared to control mice 21 days after re-challenge with 0.2e
6
 B16F10 cells 
injected IV n=2-6 mice/group. Scale bars for top right box = 120M. Scale bars 
for bottom right box = 175M. (C) Quantification of percent of lung taken up by 
tumor as determined by microscopic examination (mean  SEM); n=2-6 
mice/group. Mean percent area compared by one-way repeated measures 




tumors. Despite causing aggressive tumor outgrowth in the lungs of control mice, 
the lungs of all mice previously treated with either intermediate or late Th17 cells 
were protected from metastasis (Figure 4-15B). We performed histological 
analysis of the lungs to confirm our macroscopic observations of no metastatic 
tumor growth. Stepped sections were cut through whole lung blocks (which 
included the heart and surrounding structures) from each group to determine the 
presence of any macro or microscopic metastatic tumor deposits. In concordance 
with macroscopic findings, clear tumor nodules were noted in control lungs while 
no melanoma deposits were seen in any of the other treatment groups (Figure 4-
15B). In control mice, tumor occupied ~61% (4.5%) of the total lung volume 
(Figure 4-15C). These results highlight the capacity of long-term expanded Th17 
cells to eradicate tumors and provide durable protection from tumor metastasis. 
 
Human Th17-polarized, but not Th1-polarized cells retain antitumor activity 
after expansion 
As an important step towards translation of this work to clinical trials, we 
sought to determine if human Th17 cells possess the same undiminished capacity 
to clear tumors after long-term expansion as murine Th17 cells. We expected that 
human Th17 cells would remain highly therapeutic while Th1 cells would decline 
in efficacy after expansion, similar to our observation with murine Th17 versus Th1 




Th1 cells, human CD4+ T cells from the peripheral blood of normal donors were 
polarized to either a Th17 or Th1 phenotype. These two subsets were then 
expanded for ~2 weeks after activation with anti-CD3 beads coated with ICOS and 
CD28, and redirected to express a chimeric antigen receptor that recognizes 
mesothelin and signals CD3 and 4-1BB (MesoCAR). We also expanded bulk 
CD8+ T cells with CD3/CD28/ICOS beads and IL-2, and engineered them with the 
same MesoCAR construct. During expansion, Th17 cells became more poly-
functional with increased capacity to secrete IFN and IL17A (Figure 4-16A). 
Interestingly, at all time points human Th17-polarized cells secreted more IFN 
than human Th1-polarized cells. This may be because among the cells derived 
from the peripheral blood were mature T cells which may have had prior functional 
profiles before polarization compared to the mainly naïve T cells from TRP-1 
mouse spleens.  
However, Th17 polarization did induce high expression of the Th17-
associated CCR6 chemokine which was largely absent on Th1-polarized cells 
(Figure 4-16B), and both Th1 and Th17 cells both expressed similar levels of 
CXCR3, a chemokine receptor associated with Th1 cells. Thus, a large portion of 
Th17 cells became double positive for CCR6 and CXCR3 by the end of culture, a 
phenotypic marker of a highly functional non-classical Th17/Th1 hybrid cell (Figure 
4-16B) (188). Additionally, Th17 cells with the highest CCR6 expression also 
expressed CCR5 and CCR10, two chemokine receptors important for trafficking to 
inflamed tissues (189, 190) (Figure 4-17A-B). While present, these chemokines   
 
107 
   
Figure 4-16. Human CD4+ T cells polarized to Th17 cells exhibit increasing 
polyfunctionality during ex vivo expansion.  
(A) IL-17A and IFN expression by human Th17 and Th1 polarized cells 
expanded for 3, 6, 9, or 12 days in vitro, representative of 2 normal donors. (B) 
CCR6 and CXCR3 expression on human Th17 and Th1 polarized cells 





Figure 4-17. Th17 cells display a wide array of receptors for inflammatory 
chemokines and higher effector memory frequencies ex vivo than Th1 cells.  
(A) CCR6 and CCR5 expression by human Th17 and Th1 cells expanded for 3, 
6, 9, or 12 days in vitro, representative of 2 normal donors. (B) CCR6 and 
CCR10 expression on human Th17 and Th1 cells expanded for 3, 6, 9, or 12 
days in vitro, representative of 2 normal donors. (C) CD62L against CD4 
expression on human Th17 and Th1 cells expanded for 3, 6, 9, or 12 days in 




were at lower concentrations on Th1 cells. Human Th17 and Th1 cells also showed 
a similar memory marker pattern with murine T cells as human Th1 cells expressed 
more CD62L at the beginning of culture than human Th17 cells (Figure 4-17C). 
However, by day twelve, both subsets had less CD62L expression indicating a 
progressive shift to an effector memory phenotype (Figure 4-17C).  
To test whether human Th17-polarized cells preserved antitumor activity 
during ex vivo expansion, we infused seven or twelve day expanded 
MesoCAR+Th17 cells (2e6/mouse) with twelve day expanded MesoCAR+CD8+ T 
cells (2e6/mouse) into NSG mice with established M108 mesothelioma tumors. As 
a control, we also treated mice with seven or twelve day expanded MesoCAR+Th1 
cells (2e6/mouse) with twelve day expanded MesoCAR+CD8+ T cells (2e6/mouse). 
We found that MesoCAR+Th17 cells eradicated human mesothelioma regardless 
of expansion time (Figure 4-18A). Conversely, treatment with twelve day expanded 
CAR+Th1 mediated poor antitumor activity compared to treatment with seven day 
expanded CAR+Th1 cells (Figure 4-18A). Importantly, Th17 cells could not mediate 
tumor immunity if engineered with a CAR against CD19 (Figure 4-18B). This is not 
surprising as mesothelioma tumor do not express CD19 antigen. Also, we tested 
the benefit of antigen specific mesoCAR+CD8+ T cells in our human model by co-
transferring mesoCAR+Th17 cells with CD19CAR+ CD8+ T cells. While antigen 
specific Th17 cells with CD19CAR+CD8+ T cells controlled tumor growth well (and 
better than mesoCAR+CD8+ T cells transferred with CD19CAR+Th17 cells), we 




antigen specific against the correct target, mesothelin (Figure 4-18B). Collectively, 
our data reveal that human Th17 cells retain their antitumor capacity when 
expanded long-term ex vivo. Our human study confirms our findings that durable 
Th17 cells generated from ex vivo expansion which dramatically eliminated large 
and metastatic melanoma tumors in mice, translates to human T cells with major 






   
Figure 4-18. Human Th17 cells retain antitumor efficacy after two weeks of ex 
vivo expansion while Th1 cells do not.  
(A) M108 tumor burden of NSG mice treated with 2e
6





Th1 cells with 2e
6





 T cells, compared to no treatment; n=8-11 mice/group. (B) 







day expanded Th17 and CD8
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ACT therapy mediates objective response rates in ~50% of cancer patients. 
This therapy relies on the infusion of large numbers of T cells (1011) to achieve this 
goal. Although CD8+ T cells are often used for ACT, they lose efficacy as they 
expand ex vivo. Herein, we discovered that Th17 cells have an undiminished 
capacity to regress tumors as they expand. Transferring 2e6 Th17 cells expanded 
for 3 weeks ex vivo mediated similar antitumor immunity in mice as infusing 2e6 
“younger” Th17 cells expanded for one week. In contrast, neither Th1 nor CD8+ T 
cells retained antitumor efficacy after only two week’s expansion. Thus, on a per 
cell basis, the antitumor capacity of Th17 cells is more effective than Th1 or CD8+ 
T cells after long-term ex vivo expansion. 
We hypothesized that the retention of antitumor efficacy by Th17 cells, 
coupled with their expansion to large numbers over 3 weeks would allow us to treat 
large recalcitrant melanoma tumors (~175mm2) by treating mice using the entire 
cell product. Indeed, this high dose Th17 therapy eradicated tumors in mice and 
mediated curative responses for more than 6 months. Also, our cured animals 
were protected from a subsequent tumor re-challenge both subcutaneously and 
intravenously to model aggressive lung metastases. In contrast, the few Th17 cells 
expanded for only one week were insufficient to clear even primary tumors. To our 
knowledge, this is the first report that investigates concomitantly 4 factors critical 




Our findings are relevant as they provide key insight into the potency of Th17 cells, 
which expand robustly without diminishing in quality.  
We and other investigators have reported beneficial traits of Th17 cells for 
ACT (85, 88, 93). Unlike Th1 cells, Th17 cells do not express KLRG1 or TIM3 
during expansion while cytokine receptors and costimulatory molecules are more 
abundant on Th17 cells than Th1 cells. Moreover, although resistance to apoptosis 
in Th17 cells has been reported (88, 191), we provide evidence that their 
resistance to apoptosis is continuous throughout in vitro culture. We suspect that 
these attributes also permit Th17 cells to persist in the harsh tumor 
microenvironment. 
Effector memory CD8+ T cells (CD62L-) are far less effective at regressing 
tumors when infused into mice or humans compared to their less differentiated 
counterparts, such as stem and central memory CD8+ T cells (46, 47, 60). This 
observation begs the question: how can early or late effector memory Th17 cells 
that express nominal CD62L persist and still regress tumors in vivo? While 
previous studies indicate Th17 cells have active -catenin signaling after short in 
vitro expansion (85), our western blot analysis of tumor-reactive Th17 cells found 
the transcription factor Tcf7 present in the nucleus at all time-points during 
expansion. This observation is insightful, as Tcf7 is an essential protein in the 
Wnt/-catenin pathway critical for stem memory T cell self-renewal and very 




asymmetric T cell division (85, 183). Therefore, we posit that constitutive Tcf7 
signaling may partially explain why Th17 cells expand robustly in a petri dish and 
persist long-term in vivo. This finding might also explain why Th17 cells maintain 
their telomere length in vitro and in vivo, a property directly associated with T cell 
persistence in patients with enhanced survival in ACT trials (53-55).  
We found Th17 cells are capable of directly lysing tumors. Both early and 
late-expanded donor Th17 cells regressed melanoma independent of host CD8+ T 
cells, as antibody depletion of CD8+ T cells did not compromise treatment 
outcome. This is in alignment with a report by the Antony lab (99) that found tumor-
reactive CD4+ T cells clear tumor in a class-II-restricted manner in vivo. However, 
in our human CAR model, we found that infusion of both antigen specific Th17 
cells and CD8+ T cells was needed to mediate optimal antitumor responses, as 
MesoCAR+Th17 cells were unable to eradicate the tumors when co-infused with 
non-specific CD8 T cells (i.e. CD19CAR+CD8+ T cells) (Figure 4-18B). This finding 
agrees with a study by the Dong laboratory (97) which found that depletion of 
endogenous CD8+ T cells diminished the antitumor response of Th17 cells, though 
it did not abrogate it completely. It is also important to appreciate that a possible 
confounding variable of depleting host CD8+ T cells in our TRP ACT melanoma 
model would be the creation of space for the donor Th17 cells to engraft and better 
consume homeostatic cytokines (82, 138). Collectively, our data support a 




with other immune cells, such as CD8+ T cells, to protect the host from tumor 
relapse long-term. 
Based on recent evidence supporting the benefit of shorter preparation time 
for ACT cell products (46, 192), cancer immunotherapists are devoting significant 
effort to reduce T cell expansion time ex vivo before infusion. A clinical trial at the 
NCI reported that they could generate “young TILs” that could mediate improved 
regression of metastatic melanoma. Yet, these TIL products were still expanded 
for a month ex vivo before return to the patient (87). Additionally, it is important to 
note that many parameters besides time contribute to CD8+ T cell exhaustion/loss 
of efficacy including: the number of times the T cells are re-stimulated, the growth 
factor cytokines used (IL-2 vs. IL-15 vs. IL-21) and the type of co-stimulatory 
signals (CD28, ICOS or 41BB) delivered to expand the cells, which can alter their 
bioenergetics (43, 48, 69, 76, 94, 107). In particular, IL-2 is the staple growth factor 
used to expand TIL and CAR-T cells for ACT. But, while this cytokine has potent 
effect on proliferation, IL-2 also differentiates CD8+ T cells to an effector or terminal 
status (67). These considerations give further credence to the use of T cells with 
stemness, such as Th17 cells or pharmacologically altered CD8+ T cells (60, 85, 
120, 121) both of which expand long-term without reaching terminal differentiation.  
Of clinical importance, human CAR+Th17-polarized cells also retain their 
antitumor potency after long-term expansion while human CAR+Th1-polarized 




xenograft model of mesothelioma were superior to that of CAR +Th1 after either 
seven or twelve days of ex vivo expansion. These findings recapitulate those in 
our TRP-1 melanoma model where murine Th17 cells mediate greater tumor 
immunity than TRP-1 Th1 cells. Of note, while the shortest reported TIL expansion 
protocols still require one month of ex vivo expansion, our data with 12-day 
expanded human Th17 CD4+ T cells are particularly relevant in the context of CAR 
therapies where many T cells can be quickly generated from peripheral blood 
within one or two weeks post-apheresis.  
In closing, Th17 cells offer promise for next generation ACT trials, as they 
can: 1) expand rapidly in vitro for three weeks without requiring re-activation, 2) re-
populate the host after infusion regardless of ex vivo expansion time and 3) 
mediate potent destruction of large tumors when the total number of cells 
generated after 2 or more weeks of ex vivo culture is used. Th17 cell durability may 
also result in more consistent success in generating a therapeutic cell product, due 
to a larger window of opportunity for securing potent T cells after ex vivo expansion. 
The resilience of Th17 cells in vitro may also simplify clinical preparation rendering 
them more feasible to prepare for clinical trials in many cancer centers around the 





Chapter 5: PI3K inhibition fortifies tumor-reactive murine and human CD8+ 




Adoptive cell therapy (ACT) for cancer allows for the enrichment of T cells 
optimally suited to exert antitumor immunity. When these T cells express a less 
differentiated memory phenotype with high levels of the lymphoid homing 
molecules CD62L and CCR7, they induce high rates of objective responses and 
long-term survival (50, 62). Conversely, preclinical murine models of ACT indicate 
that not only are fully differentiated effector CD8+ T cells ineffective at clearing 
tumors (46), but having effector cells within the cell product corrupts the antitumor 
potential of the entire population (192). The improved antitumor efficacy of less 
differentiated T cells is due in part to an improved capacity to engraft and persist 
long-term in the host. This may be due not only to improved trafficking to lymphoid 
tissues, but also improved capacity to respond to homeostatic cytokines (73). 
Additionally, stem memory T cells (Tscm) which are the least differentiated of the 
memory subsets and express active Wnt/-catenin signaling, show the greatest 
capacity to clear tumors and provide long-term immunity (60). 
Thus, a major pursuit in the ACT field is to select and preferentially expand 
T cells in a less differentiated state. Particularly exciting are methods which 




strategies have emerged including blockade of -catenin degradation (60), 
increasing/strengthening mitochondrial networks to mimic those seen in memory 
T cells (107), denial of glucose via a small molecule inhibitor (103) or inhibition of 
the PI3K/AKT axis (120, 121).  
The PI3K/AKT axis plays an integral role in T cell activation downstream the 
TCR and is important for clonal expansion and cytokine production (110). It also is 
involved in memory formation, as AKT phosphorylates and sequesters FOXO 
transcription factors preventing transcription of CD62L, CCR7, CD127 and other 
molecules associated with less differentiated T cells (193). Patients who have an 
overactive PI3K also show rapid proliferation and terminal differentiation of their 
CD8+ T cells with resultant chronic inflammation and susceptibility to viral infection 
(114, 115). Additionally, murine models which knock out the main kinase subunit 
of PI3K in lymphocytes (P110), show reduced proliferation and weak cytokine 
production by CD8+ T cells in viral infection (116, 118). While memory formation in 
these models was intact, the low numbers of memory T cells formed after primary 
infection led to an impaired memory response during a secondary challenge (117, 
119).  
Yet, in contrast to the weak CD8+ T cell immunity in P110 knockout T cells, 
T cells which are treated with a small molecule inhibitor of AKT exert stronger 
antitumor responses in both GVL and melanoma (120, 121). These studies 
indicate that genetic ablation and pharmaceutical inhibition of PI3K signaling do 




AKT is often considered the same, PI3K interacts with multiple other kinases 
besides AKT including MAPK and PKC kinases (122-124), as well as other AGC 
family kinases through the downstream kinase PDK1 (125). Thus, we 
hypothesized that pharmaceutical inhibition of p110 will endow tumor-reactive T 
cells with a more potent memory phenotype than direct AKT inhibition.  
We tested our hypothesis in both murine transgenic TCR pmel-1 T cells and 
human peripheral blood CD3+ T cells. These cells were treated with either the 
P110 inhibitor CAL-101, or the AKT1/2 inhibitor AKT VIII (AKTi). We found that in 
both murine and human T cells CAL-101 induced memory marker expression of 
CD62L and CCR7 similarly to AKT. CAL-101 also induced the alpha receptor for 
IL-7 (CD127) to a much greater extent than AKTi suggesting these cells might 
engraft better in the hosts than even AKTi treated cells (73). Indeed, CAL-101 
treated T cells had the highest levels of circulating as well as tumor infiltrating 
donor cells which corresponded with improved tumor control and lengthened 
survival. Interestingly, PI3K blockade upregulated activity of -catenin greater 
than AKTi as shown by increased levels of Tcf7 in the CAL-101 treated cells. 
Interestingly, when we tested the importance of CD62L expression and CD127 
expression to the antitumor potency of CAL-101 primed T cells, we discovered that 
sorting CD62L from IL-2 expanded conventional tumor-reactive T cells could not 
recapitulate the potency of CAL-101 priming. Additionally, depletion of IL-7 did not 
abrogate the capacity of CAL-101 primed T cells to clear tumor. These results 




T cells may provide a distinctly potent cellular product for ACT with improved 
capacity to control malignancies. 
 
Pharmaceutical inhibition of p110 in pmel-1 CD8+ T cells increases both 
CD62L and CD127 expression without hindering expansion 
To test whether PI3K inhibition enhanced the antitumor capacity of tumor-
reactive T cells compared to direct AKT inhibition, CD8+ T cells from pmel-1 
transgenic mice (CD8+ T cells with a transgenic TCR specific for the 
melanoma/melanocyte antigen gp100) were activated with their specific antigen 
and treated with vehicle control, AKTi as previously published (121), or CAL-101 
throughout culture (see methods). As expected, drug treatment induced marked 
differences in memory. While 65% of vehicle treated CD8+ T cells expressed 
CD62L, nearly all cells treated with AKTi or CAL-101 expressed CD62L (97% and 
100% respectively, see Figure 5-01A). Interestingly, the MFI of CD62L on CAL-
101 treated T cells was higher than on those treated with AKTi. While both drug 
treatments lowered the activation marker CD69, CAL-101 had a much stronger 
effect on diminishing the MFI of CD44 (Figure 5-01B). While this CD44loCD62Lhi 
phenotype mimicked the phenotype of antigen naïve T cells, CAL-101 treated cells 
expanded to similar levels as both vehicle and AKTi treated cells. This suggests 
that despite PI3K inhibition, T cell receptor and downstream proliferative signaling 





Figure 5-01. CAL-101 priming supports a de-differentiated memory phenotype 
including high IL-7R expression on pmel-1 CD8
+
 T cells.  
(A) Representative flow plots of CD44 by CD62L expression on pmel-1 CD8
+
 T 
cells primed with vehicle, AKTi or CAL-101 after 5 days of culture; representative 
of 3 independent cultures. (B) MFI of CD62L, CD69 and CD44 on pmel-1 CD8
+
 
T cells after 5 days of culture; n=3 independent cultures. One way repeated 
measures ANOVA; ** = p<0.01, *** = p<0.001, **** = p<0.0001. (C) Fold growth 
and fold increase of pmel-1 CD8
+
 T cells primed with vehicle (DMSO), AKTi, or 
CAL-101 5 days following antigen stimulation; n=3 independent cultures. (D) 
MFI of CD25 and CD127 on pmel-1 CD8
+
 T cells after 5 days of culture; n=3 
independent cultures. One way repeated measures ANOVA; ns = not 




CD8+ T cells denied PI3K signaling via CAL-101 engraft at higher levels in 
vivo and maintain CD62L and CD127 expression 
While both drugs slightly lowered CD25 (IL-2 receptor alpha) on T cells in 
vitro, they substantially elevated CD127, the alpha receptor for IL-7 (Figure 5-01D). 
Signaling through this receptor is important for sustaining naïve and central 
memory T cells (72), and supports high numbers of donor cells in the host (73). 
We therefore hypothesized that both drug treatments would improve the 
engraftment of donor cells and subsequent antitumor immunity. Interestingly, one 
week post-treatment, we found that only CAL-101 treatment profoundly increased 
donor frequency in the blood. Additionally, while both AKTi and CAL-101 increased 
CD62L expression in vitro, only CAL-101 treated T cells retained significantly more 
CD44hiCD62Lhi and fewer CD44hiCD62Llo circulating cells compared to the other 
treatments (Figure 5-02A). Additionally, while both AKTi and CAL-101 had fewer 
PD1+ donor cells, only CAL-101 reduced the frequency of donor cells expressing 
the exhaustion marker KLRG1 (Figure 5-02A). CAL-101 treated CD8+ T cells also 
retained a far larger portion of CD127+ T cells than the other groups (Figure 5-
02A). CAL-101 donor T cells were similarly found at higher levels than AKTi and 
vehicle donor cells within the spleen and draining (inguinal) lymph nodes of the 






Figure 5-02. CAL-101 primed T cells preserve dedifferentiated phenotype in vivo 
and persist at higher numbers.  
(A-B) Frequency of donor pmel-1 T cells and extracellular markers on pmel-1 
donor T cells in (A) blood and (B) tumor 7 days following treatment; n=3 
mice/group. One way repeated measures ANOVA; ns = not statistically 




T cells treated with CAL-101 effectively infiltrate the tumor, arresting tumor 
growth and prolonging survival 
We expected that the retention of a less differentiated memory phenotype 
and high CD127 by CAL-101 treated cells in circulation would translate to higher 
donor cell numbers in the tumor and therefore, improved antitumor immunity. 
Again, we observed a higher frequency of CAL-101 treated T cells in the tumor 
compared to control treated T cells. Surprisingly, there were also more central 
memory CAL-101 treated cells in the tumor. However, percentage of PD1+ and 
KLRG1+ donor cells in the tumor were similar between groups (Figure 5-02B). Yet, 
CAL-101 cells slowed the growth of B16F10 melanoma in mice (Figure 5-03A-B), 






Figure 5-03. CAL-101 primed pmel-1 CD8+ T cells exert stronger antitumor 
response against B16F10 tumors.  
(A) Tumor burden (mm
2
) of individual mice which received no T cell treatment, 




 T cells primed with vehicle, AKTi, or CAL-101; n=10-12 
mice/group. (B) Average tumor burden (mm
2
) of treatment groups; n=10-12 
mice/group. (C) Percent survival of above treatment groups; n=10-12 




CAL-101 induces Tcf7 signaling in human central memory T cells  
We next determined if pharmaceutically inhibiting PI3K would also 
augment the fitness and memory properties of human T cells. To address this 
question, we similarly treated human CD3+ T cells isolated from peripheral blood 
mononuclear cells of healthy donors with CAL-101 and expanded them with 
CD3/CD28 beads. We found that CAL-101 treated cells had slightly lower levels 
of CD45RO, a marker of T cell maturation, and the highest CCR7 (Figure 5-04A-
B). PD1 was nominally expressed on all groups, however both PI3K and AKT 
blockade prevented upregulation of TIM3 post-activation compared to untreated T 
cells (Figure 5-04C). PI3K blockade with CAL-101 had little impact on CD25 but 
greatly increased CD127 on T cells (Figure 5-04C-D).  
Given that T cells treated with CAL-101 were effective in preventing the 
growth of melanoma long term, we suspected that PI3K signaling bolsters 
stemness. To determine if PI3K blockade induced Wnt/-catenin signaling in T 
cells, we assayed the levels of nuclear -catenin and the downstream transcription 
factors Lef1 and Tcf7. While nuclear -catenin was similar between groups, drug 
primed T cells evidenced increased transcriptional activity by -catenin as 
indicated by slightly higher Lef1. However, PI3K blockade uniquely increased 
nuclear Tcf7 to significant levels (Figure 5-05A-B). Thus, while the phenotype of 
AKT inhibited T cells resembles that of potent central memory T cells, 
PI3Kblockade induces a stem memory phenotype in T cells known to exert an 





Figure 5-04. PI3K blockade induces central memory phenotype in human 
polyclonal CD3
+
 T cells similar to AKTi.  
(A) CD44 and CD62L expression on vehicle, AKTi, or CAL-101 treated T cells; 
representative of 9 donors. (B) MFI of CD45RO, CD62L and CCR7 on human 
CD3
+
 T cells sorted from peripheral blood; n=9 normal donors. One way 
repeated measures ANOVA; * = p<0.05. (C) Frequency of human CD3
+
 T cells 
expressing PD1, TIM3, CD25 and CD127; n=9 normal donors. One way 
repeated measures ANOVA; ** = p<0.01. (D) Histogram of CD127 expression 
on vehicle, AKTi, or CAL-101 treated T cells compared to no stain with frequency 




Figure 5-05. PI3K blockade upregulates Tcf7 in human polyclonal CD3
+
 T cells.  
(A) Western blot of nuclear protein extracts from vehicle, AKTi, or CAL-101 
treated T cells, B = -catenin, L = Lef1, T = Tcf7, H = Histone H3; representative 
of 4-6 donors. (B) Quantified protein levels relative to Histone H3, RROD GOI/H 
= relative ratio of optical density (gene of interest over Histone H3); n=4 -6 
normal donors. One way repeated measures ANOVA; ns = not statistically 




PI3Kblockade augments the antitumor activity of human CAR-T cells 
Based on the stem memory phenotype of CAL-101 primed human T cells, 
we hypothesized that treating a human tumor with CAL-101 primed CAR-T cells 
would improve antitumor control over treatment with AKT inhibited T cells. To 
address this idea, we transduced human T cells with a lentiviral vector containing 
the 4-1BBzeta anti-mesothelin CAR (38), expanded them for seven days with IL-2 
or treated with AKTi or CAL-101, and transferred them into mice bearing 
subcutaneous mesothelioma. While all treatment groups reduced tumor burden in 
the mice (Figure 5-06A), only CAL-101 treated mice remained in remission from 
baseline after 51 days of treatment (Figure 5-06B-C). Thus, CAL-101 priming of T 
cells for ACT may provide more consistent antitumor responses for patients with 





Figure 5-06. CAL-101 primed mesoCAR-T cells exert stronger antitumor 
immunity.  





 mesoCAR-T cells primed with vehicle, AKTi, or CAL-101; n=8-12 
mice/group. (B) Percent change in size of tumors 71 days post-treatment 
compared to baseline tumor measurement at time of treatment; n=8-12 
mice/group. (C) Tumor weight at day 71 post-transfer; n=8-12 mice/group. (D) 
Frequency of human CD45
+
 lymphocytes within the blood of treated mice 55 
days post-transfer; n=2-12 mice/group. One way repeated measures ANOVA; 




Antitumor potency induced by PI3K inhibition is not due to CD62L 
CD62L expression on T cells correlates with improved antitumor immunity 
in pre-clinical ACT tumor models (46-48, 50, 192) and enriching central memory T 
cells from peripheral blood and redirecting them with a CD19 specific CAR has 
shown efficacy in an early clinical trial (62). Additionally, our studies corroborated 
these data showing a correlation between retained CD62L expression in vivo by 
CAL-101 treated donor cells and prolonged tumor control (Figure 5-02 and 5-03). 
Thus, we hypothesized that CD62L expression is responsible for a successful 
memory immune response against cancer. To better clarify the role of CD62L in 
tumor immunity, we sorted CD62L+ T cells from vehicle treated pmel-1 T cells and 
compared their antitumor impact against B16F10 to bulk vehicle T cells (which 
were 48% CD62L+) and CAL-101 treated T cells (which were 100% CD62L+, see 
Figure 5-07A). We suspected that both the CD62L+ vehicle group and CAL-101 
group would exert similar tumor control given they possess a central memory 
phenotype. But surprisingly, sort CD62L+ pmel-1 cells from vehicle cultures did not 
improve treatment outcome over therapy with bulk vehicle. In contrast, CAL-101 
mediated prolonged antitumor control (Figure 5-07B) and better survival (Figure 5-
07C) in mice. Thus, while T cells capable of long-lived memory responses against 
tumor do express CD62L, enriching cells after ex vivo expansion that express this 





Figure 5-07. The antitumor potency of CAL-101 primed T cells is CD62L 
independent.  
(A) Post-sort analysis of CD62L expression against V13 on pmel-1 T 
cells.  sorted by fluorescence activated cell sorting as CD62L
+
, or T cells treated 
with CAL-101. (B) Mice with B16F10 were treated with 8x10
5
 bulk vehicle, 
CD62L
+
 vehicle or CAL-101 pmel-1 cells compared to no treatment; n=7 
mice/group. (C) Percent survival of mice treated with vehicle primed T cells, 
vehicle primed CD62L
+
 T cells, or CAL-101 primed T cells; n=7 mice/group. 




The efficacy of PI3K blockade T cell therapy is independent of IL-7 
signaling 
PI3K blockade induced CD127 on murine T cells in vitro. Moreover, CD127 
was sustained on CAL-101 treated T cells after transfer (Figure 1D-E). This drug 
also induced high CD127 on human peripheral CD3+ T cells Figure 3C-D). We 
therefore posited that CAL-101 T cells thrived in vivo due to their enhanced 
responsiveness to IL-7. Thus, we tested the importance of IL-7 in the pmel-1 
B16F10 model by depleting IL-7 for the first two weeks after transfer, as previously 
published (73). We suspected that depleting IL-7 would decrease engraftment of 
the donor cells and impair their control of the tumor. In contrast, we found that 
while CAL-101 primed T cells engrafted at significantly higher numbers than 
vehicle or AKTi treated T cells in both isotype and IL-7 depleted mice, there was 
no significant difference between the CAL-101 treatment groups in frequency or 
memory phenotype (Figure 5-08A-B). CAL-101 primed T cells also exerted their 
prolonged antitumor immunity whether IL-7 had been depleted or not (Figure 5-
09A) which resulted in no differences in survival between the CAL-101 T cell 
groups (Figure 5-09B).  
Thus, based on these data, the antitumor capacity and engraftment of CAL-
101 primed T cells appears to be IL-7 independent. However, it is probable that 
the administration of the anti-IL-7 antibody was insufficient to deplete IL-7 and that 
the higher expression of CD127 on the CAL-101 primed T cells allowed for 
successful scavenging of this cytokine. Additionally, we administered IL-2 complex 




compensated for IL-7, though the mechanisms of these two cytokines are not 
redundant (65). Future studies using T cells from Il7r conditional knockout mice 
may determine the importance of CD127 to the longevity of CAL-101 primed T 





   
Figure 5-08. Depletion of IL-7 does not alter numbers or memory phenotype of 
donor CAL-101 T cells.  
(A-B) Analysis of in vivo numbers and memory phenotype of transferred pmel-
1 T cells primed with vehicle, AKTi, or CAL-101 10 days after transfer into (A) 
isotype or (B) IL-7 depleted mice; n=5 mice/group. One way repeated measures 
ANOVA; ns = not statistically significant, * = p<0.05, ** = p<0.01, *** = p<0.001, 






Figure 5-09. The antitumor potency of CAL-101 primed T cells is CD127 
independent.  
(A) Individual tumor burden of isotype or IL-7 depleted mice receiving vehicle, 
AKTi, or CAL-101 primed donor cells; n=10 mice/group. (B) Percent survival of 
mice in panel A; n=10 mice/group. Kaplan Meier curve analyzed by log rank 
test; ns = not statistically significant, ** = p<0.01. (C) Percent specific lysis of 
hgp100 loaded splenocytes by CAL-101 primed pmel-1 T cells in isotype treated 
or IL-7 depleted mice 53 days post-transfer; n=6-7 mice/group; ns = not 





Collectively, our data indicate that while PI3K is upstream of AKT, its 
blockade through inhibition of p110 induces stronger memory in CD8+ T cells than 
AKT inhibition. Furthermore, while inhibition of either PI3K or AKT supports the 
generation of central memory T cells, we found that PI3K blockade preferentially 
increases CD127 and the stem memory transcription factor Tcf7. Additionally, 
PI3K blockade improved the antitumor response of both murine and human 
tumor-reactive T cells over that of traditionally expanded (vehicle) or AKTi-treated 
T cells. We set out to determine if CD62L and CD127 were responsible for the 
enhanced antitumor immunity of CAL-101 memory T cells. Our studies offer early 
evidence that the longevity of immune responses exerted by memory T cells 
cannot be explained by CD62L or CD127 expression alone. This was evidenced 
by the poorer antitumor immunity of sorted CD62L+ T cells from vehicle expanded 
T cells compared to CAL-101 primed T cells. Additionally, in vivo blockade of IL-7 
was insufficient to impair the antitumor efficacy of CAL-101 primed T cells. 
Successful immunity against both viral infections and cancer requires long-
term protection provided by memory cells (52). We have classically associated T 
cell memory with expression of surface markers such as CD62L, CCR7 and 
CD127 (58, 72), which were increased in both AKTi and CAL-101 treated T cells. 
Thus both P110 and AKT inhibition seem to prevent phosphorylation of FOXO 
transcription factors by AKT (193) as we expected. However, the level of these 




antitumor response, indicating that other pathways were being altered uniquely by 
CAL-101 treatment. One pathway which is consistently associated with durable 
memory T cells is the Wnt/-catenin pathway, whether it be active in stem memory 
T cells (60, 64) or in Th17 cells (85). We found that CAL-101 increased Tcf7 
expression in human T cells significantly above vehicle while AKTi inhibition did 
not. As the Wnt/-catenin pathway interacts with FOXO transcription (194, 195), 
this may explain why receptors such as CD62L, CCR7 and CD127 were higher in 
these cells. However, as PI3K blockade augmented antitumor potency in an 
apparent CD62L and IL-7 independent manner, we suspect that the contribution 
of Tcf7 to the memory of T cells cannot be described solely by potentiation of 
FOXO derived memory. Thus, future studies with Tcf7 knockout T cells will help 
us understand the role and mechanism of Tcf7 in enhancing memory due to PI3K 
blockade. 
Among the class 1A catalytic subunits of PI3K, P110is expressed mainly 
in the hematopoietic lineage (196) while P110, and  are thought to play a 
minimal role (108, 109). This corroborates with early studies in our lab using 
specific inhibitors of the other subunits which did not generate T cells with the same 
antitumor potency as P110 blockade (not shown). Yet, while CAL-101 treatment’s 
potentiation of T cell memory appears to be unique to P110 blockade, CAL-101 
also has reported effects on the class II, III and IV PI3Kinases when used at doses 
similar to what we used to treat our T cells (197). Therefore, the effects on T cells 




experiments with P110 knockout mice with or without CAL-101 treatment will 
further elucidate the way in which CAL-101 primes T cells to exert more powerful 
antitumor immunity. 
Inducing a durable memory phenotype through reversible pharmaceutical 
manipulation of PI3K is an attractive way of generating potent memory T cells. 
Yet, while CAL-101 T cells exerted a longer antitumor response than vehicle and 
AKTi treated T cells, they eventually lost control of the tumor in most mice (Figure 
2B). We found that as early as one week after transfer, these cells were expressing 
similar levels of PD-1 and KLRG-1 compared to vehicle and AKTi treated T cells 
(Figure 2A). Thus, while PI3K blockade induces a strong memory phenotype 
including high Tcf7 expression, it does not appear to protect the cells from 
inhibitory signaling and exhaustion. We posit that a combination of PD-1 
checkpoint blockade therapy may prevent the reestablishment of immune 
tolerance observed in donor CAL-101 cells and allow for continued tumor control. 
Additionally, while we demonstrate the power of ex vivo priming with CAL-
101 to enhance the antitumor function of T cells, we recognize that there may be 
other viable strategies for employing this drug. It may be especially powerful to add 
CAL-101 treatment in combination with extant immunotherapies to boost the 
effector function of tumor-reactive T cells. For example, in addition to its capacity 
to boost effector T cells, its direct cytotoxic effects on cancers (198) as well as its 
ability to break immune tolerance (199) are well known and may synergize well 




Nonetheless, whatever the route of application may be, we submit the use 
of CAL-101 as a viable and potent method for enhancing immune-based therapies 





Chapter 6: Improving ACT outcomes by amplifying memory in tumor-




For patients diagnosed with metastatic disease, the advent of 
immunotherapy has changed the expectation for the level and frequency of 
responses and complete remissions. Adoptive T cell therapy (ACT) for cancer is 
one of the most exciting immunotherapies with unprecedented levels of complete 
responses in patients who receive this treatment (27). In its simplest form, ACT 
involves the procurement, ex vivo selection, and expansion of autologous tumor-
reactive T cells for reintroduction into a lymphodepleted host. However, we are 
finding that each step of this process can impact the T cell’s fitness with marked 
impact on the therapeutic outcomes. One fundamental rule emerging from recent 
studies is to ensure that the T cells transferred have a memory phenotype capable 
of inducing long-term immunity in the patient. Currently, three of the hallmarks of 
T cells capable of a long-lived antitumor response: 1) CD62L and/or CCR7 
expression, 2) Wnt/-catenin signaling and Tcf7 expression, and 3) high 
responsiveness to homeostatic cytokines, especially IL-7. Herein, we examine 
how the different elements of ACT effect the memory and resultant antitumor 
efficacy of a T cell product. This included investigating: 1) how preconditioning 




benefit of using Th17 T cells with durable stem memory and long-lived antitumor 
responses, and 3) a pharmaceutical method to induce memory in T cells by 
blocking PI3K signaling.  
We found that while TBI preconditioning enhances and prolongs the 
antitumor efficacy of Tc17 cells more than Tc0 cells. However, this was not due to 
enhanced CD62L expression, but rather due to IL-12 induced polyfunctionality 
including a stronger cytokine production upon antigen reintroduction. Th17 cells 
generated by cytokine polarization of both murine and human CD4+ T cells 
expanded to large numbers but retained the capacity to persist long-term and 
eradicated tumors. We found evidence of preserved Tcf7 expression in these cells 
as well as preserved telomere length, both of which are associated with T cells 
which exert strong memory-based immunity. Finally, we found that CAL-101 
inhibition of PI3K in both murine, and human tumor-reactive T cells induced a 
strong memory phenotype. This included expression of lymphoid homing 
receptors, stem signaling and heightened levels of CD127 with enhanced tumor 
control compared to vehicle and AKTi treated T cells. 
In the setting of PI3K blockade we also tested the contribution of CD62L, 
and CD127 to the actual antitumor capacity of T cells. Interestingly, we found that 
the potency of CAL-101 treated T cells cannot be explained fully by either CD62L 
expression, or IL-7 responsiveness. We now believe that despite the drug’s short-
term and reversible direct effects on PI3K, it is inducing stable genetic 




physiology and the importance of Tcf7 to the antitumor potency of T cells are part 
of our future directions.  
Taken together, our studies show the importance of careful attention to the 
methods of T cell preparation as each part of the protocol has an influence on the 
memory and resulting potency of the T cells. We also show that defining effective 
memory via traditional ligands and receptors is not as reliable as examining the 
genetic memory imprint on those cells via stemness and mitogen signaling. We 
offer strong evidence for the use of cells which either naturally exhibit genetic 
profiles of stemness such as Th17 cells, or the use of pharmaceutically altered 
cells which have these pathways induced. We believe these findings are directly 
applicable to the current challenges in ACT including the inherent cost, technical 
difficulty and inconsistency in generating therapeutic cellular products. 
Additionally, our future efforts will better define the ways we can select, generate, 
and manipulate potent antitumor T cells.  
 
Future Directions: better understanding how to enhance memory in tumor-
reactive T cells 
Th17 cells have been described as long-lived effectors, and we have 
confirmed their ability to retain effector function and exert long-term immunity. Yet, 
it is still unclear if these properties are due to Wnt/-catenin signaling or some 
other process. While it is likely the case that Tcf7 signaling will be one of a group 




RORt, we also saw induction of Tcf7 by blockade of PI3K without RORgt 
inducing cytokine polarization. Thus, while it may not fully explain the durability of 
Th17 cells or the longevity of CAL-101 induced memory responses, we posit that 
it is vital to the memory phenotype we observed in both cell types. Thus, we are 
planning future studies using Tcf7 knockout mice which should help elucidate the 
importance of this pathway to Th17 and CAL-101 primed T cell phenotype. 
Additionally, these cells offer an excellent model system to scrutinize what drives 
long-lived memory and effector capacity. We will therefore undertake 
transcriptome analysis in these cells to search out novel drivers of T cell memory.  
The difference between drug inhibition versus genetic knockout of P110 
begs the question of how CAL-101 is inducing the memory phenotype and 
antitumor function we see in CAL-101 primed cells. We propose that another 
benefit of CAL-101 priming beyond induced memory is prevention of exhaustion 
during ex vivo expansion similar to what’s been seen in patients with overactive 
PI3K signaling (114, 115). Additionally, while CAL-101 is highly specific for the 
delta subunit by industry standards, we use concentrations which likely inhibit other 
classes of PI3K (197). We are planning future studies where P110 knockout mice 
treated with CAL-101 to see if those T cells can still achieve the memory phenotype 
and antitumor potency we see in wild-type mice. We are particularly interested in 
looking at epigenetic changes since the memory phenotype induced by CAL-101 
appears stable, in that the cells have superior antitumor efficacy long after the drug 




primed cells using the Assay for Transposase Accessible-Chromatin (ATAC) 
sequencing to understand how memory is imprinted via drug treatment.   
Compared to the T cells used currently in ACT, both Th17 cells and CAL-
101 primed T cells represent a marked improvement in effector quality and 
durability. We have experienced consistency in both ex vivo preparation, which 
requires small adjustments to current expansion protocols. Thus, we are motivated 
to design clinical trials using these two cell products. In the meantime, we are also 
aware of opportunities to use CAL-101 in the original systemic treatment format, 
recognizing that its potentiating effects on effector cells may also occur in vivo. We 
would conduct these experiments in a phase I type format to try and reduce the 
toxicity observed in systemic CAL-101 treatment while preserving its effects on 
CD8+ T cell memory. In this vein, combination therapy with CAL-101 and 
checkpoint blockade is particularly attractive to combine both effector 
enhancement with multiple mechanisms for breaking tolerance in the tumor 
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